



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12N 15/62, 15/24, A61K 38/20, 47/48, 39/395, 39/04, C07K 16/28, 14/21, 19/00, 14/57, C12N 15/31, 1/21, G01N 33/68	A1	(11) International Publication Number: WO 98/08957 (43) International Publication Date: 5 March 1998 (05.03.98)
(21) International Application Number: PCT/US97/15050 (22) International Filing Date: 27 August 1997 (27.08.97) (30) Priority Data: 08/706,207 30 August 1996 (30.08.96) US (71) Applicant: THE PENN STATE RESEARCH FOUNDATION [US/US]; 304 Old Main, University Park, PA 16802 (US). (72) Inventors: DEBINSKI, Waldemar; 1637 Macintosh Way, Hummelstown, PA 17036 (US). PURI, Raj, K.; 12527 Gooderham Way, North Potomac, MD 20878 (US). (74) Agent: MONAHAN, Thomas, J.; Intellectual Property Office, The Pennsylvania State University, 113 Technology Center, University Park, PA 16802 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i> <div style="text-align: center; font-size: 2em; font-family: cursive;">COPY</div>	
(54) Title: COMPOSITIONS AND METHODS FOR SPECIFICALLY TARGETING TUMORS		
(57) Abstract The present invention provides a method and compositions for specifically delivering an effector molecule to a tumor cell. The method involves providing a chimeric molecule comprising an effector molecule attached to a targeting molecule that specifically binds an IL-13 receptor and contacting a tumor cell with the chimeric molecule in the presence of an interleukin-4 receptor (IL-4R) blocker.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

COMPOSITIONS AND METHODS FOR SPECIFICALLY TARGETING TUMORS

5

FIELD OF THE INVENTION

This invention relates to methods of specifically delivering an effector molecule to a tumor cell. In particular this invention relates to chimeric molecules that specifically bind to IL-13 receptors which, when combined with IL-4 receptor blockers, specifically deliver compounds or having a particular activity to tumors overexpressing IL-13 receptors.

BACKGROUND OF THE INVENTION

In a chimeric molecule, two or more molecules that exist separately in their native state are joined together to form a single entity (molecule) having the desired functionality of all of its constituent molecules. Frequently, one of the constituent molecules of a chimeric molecule is a "targeting molecule". The targeting molecule is a molecule such as a ligand or an antibody that specifically binds to its corresponding target, for example a receptor on a cell surface. Thus, for example, where the targeting molecule is an antibody, the chimeric molecule will specifically bind (target) cells and tissues bearing the epitope to which the antibody is directed.

Another constituent of the chimeric molecule may be an "effector molecule". The effector molecule refers to a molecule that is to be specifically transported to the target to which the chimeric molecule is specifically directed. The effector molecule typically has a characteristic activity that is desired to be delivered to the target cell. Effector molecules include cytotoxins, labels, radionuclides, other ligands, antibodies, drugs, prodrugs, liposomes, and the like.

In particular, where the effector component is a cytotoxin, the chimeric molecule may act as a potent cell-killing agent specifically targeting the cytotoxin to cells bearing a particular target molecule. For example, chimeric fusion proteins which include interleukin 4 (IL-4) or transforming growth factor (TGF α) fused to *Pseudomonas*

exotoxin (PE) or interleukin 2 (IL-2) fused to Diphtheria toxin (DT) have been shown to specifically target and kill cancer cells (Pastan *et al.*, *Ann. Rev. Biochem.*, 61: 331-354 (1992)).

5 Generally, it is desirable to increase specificity and affinity and decrease cross-reactivity of chimeric cytotoxins with targets to be spared in order to increase their efficacy. To the extent a chimeric molecule preferentially selects and binds to its target (*e.g.* a tumor cell) and not to a non-target (*e.g.* a healthy cell), side effects of the chimeric molecule will be minimized. Unfortunately, many targets to which chimeric cytotoxins have been directed (*e.g.* the IL-2 receptor), while showing elevated
10 expression on tumor cells, are also expressed to some extent, and often at significant levels, on healthy cells. Thus, chimeric cytotoxins directed to these targets frequently show adverse side-effects as they bind non-target (*e.g.*, healthy) cells that also express the targeted receptor.

15 SUMMARY OF THE INVENTION

The present invention provides methods and compositions for specifically delivering an effector molecule to a tumor cell. In particular, the present invention provides methods and compositions for specifically targeting target tumor cells while offering reduced targeting of healthy cells than previously known methods and
20 compositions.

The improved specific targeting of this invention is premised, in part, on two discoveries: The first discovery was that tumor cells, especially carcinomas such as renal cell carcinoma, Kaposi's sarcoma, and brain tumors such as gliomas and medulloblastomas overexpress IL-13 receptors at extremely high levels. The second
25 discovery was that despite the fact that the IL-4 and IL-13 appear to share a common receptor on healthy cells, the receptors are "decoupled" in cancerous cells so that blocking of the IL-4 receptor confers protection of healthy cells without inhibiting the activity of IL-13 receptor directed molecules on cancerous cells. This permits IL-13 receptor-directed chimeric molecules (*e.g.*, IL-13R-cytotoxins) to be administered at
30 higher dosages with fewer adverse side-effects (*e.g.*, IL-13R-cytotoxins administered with an IL-4R blocker will have a higher LD₅₀). In addition, reduction and elimination

of any binding between an IL-13R directed chimera and IL-4 receptors will leave greater concentrations of the chimera free in the circulation to bind to IL-13 receptors. These features (among others) coupled with the extremely high level of IL-13 receptor expression on target tumor cells permits the specific delivery of relatively high concentrations of IL-13R-directed chimerics to their IL-13R-bearing target cells.

Thus, in one embodiment, this invention provides a method of specifically delivering an effector molecule to a tumor cell bearing an IL-13 receptor (preferably an IL-13 receptor that is not shared with IL-4). The method involves the steps of: providing a chimeric molecule comprising an effector molecule attached to a targeting molecule that specifically binds to an IL-13 receptor; and contacting the tumor cell with the chimeric molecule in the presence of a blocker of an interleukin-4 receptor (IL-4R). The blocker is preferably present in a concentration sufficient to block binding of the targeting molecule to the IL-4 receptor. The chimeric molecule thus specifically binds to the tumor cell. In a preferred embodiment, particularly where the blocker is a molecule that also occurs endogenously (*e.g.*, IL-4) the blocker is present in a concentration greater than that found in the environment in which the tumor cells and/or healthy (non-tumorous) cells normally occur. Preferred blockers include, but are not limited to an interleukin-4, an interleukin-4 antagonist, and an interleukin-4 receptor binding antibody (anti-IL-4R Ab). Interleukin-4 antagonists are selected whose antagonistic activity is mediated by binding to the IL-4 receptor not to IL-4 itself thus, they act as IL-4 competitors or competitive antagonists. Particularly preferred blockers specifically bind to the 140 kDa subunit of the IL-4 receptor. Preferred blockers include interleukin antagonists such as an interleukin-4 having a mutation in α -helix D with more preferred blockers including [Y124D]hIL4 and [R121D, Y124D]hIL4.

In preferred chimeric molecules, the targeting molecule is either a ligand, such as IL-13 or an anti-IL-13 receptor antibody. The targeting molecule may be chemically conjugated to the effector molecule, or where both targeting and effector molecules are polypeptides, the targeting molecule may be joined to the effector molecule through one or more peptide bonds thereby forming a fusion protein. Suitable effector molecules include a cytotoxin, a label, a radionuclide, a drug, a prodrug, a liposome, a ligand, and an antibody. In a particularly preferred embodiment, the

effector is a cytotoxin, (*e.g.*, *Pseudomonas* exotoxin, Diphtheria toxin, ricin, abrin, or a cytotoxic prodrug) with *Pseudomonas* exotoxin or Diphtheria toxin (especially truncated forms in which the native binding domain is eliminated) being more preferred and *Pseudomonas* exotoxin (*e.g.*, PE38QQR, PE4E, *etc.*) being most preferred. Where the *Pseudomonas* exotoxin is fused to an IL-13 targeting molecule, preferred fusion proteins include, but are not limited to IL-13-PE38QQR, IL-13-PE4E, cpIL-13-PE38QQR, and cpIL-13-PE4E.

As indicated above, the chimeric molecule is preferably contacted with the tumor cell in the presence of an IL-4 receptor (IL-4R) blocker. Preferred IL-13R-directed chimera/blocker combinations include, but are not limited to IL-13-PE38QQR or IL-13-PE4E and [Y124D]hIL4 or [R121D, Y124D]hIL4.

Preferred targets for the methods of this invention include cells, tissues, or organs that express, more preferably overexpress IL-13 receptors. Particularly preferred targets are tumor cells that overexpress IL-13 receptors. Such tumor cells include, but are not limited to renal cell carcinoma cells, brain tumor cells (*e.g.*, glioma cells, medulloblastoma cells, *etc.*), and Kaposi's sarcoma cells.

In another embodiment, this invention provides a method of impairing growth of tumor cells bearing an IL-13 receptor. The method involves contacting the tumor cell with a chimeric molecule comprising a targeting molecule that specifically binds a human IL-13 receptor; and an effector molecule selected from the group consisting of a cytotoxin, a radionuclide, a ligand, an antibody, and a cytotoxic prodrug. The contacting is in the presence of a blocker of an interleukin receptor (IL-4R). The blocker is preferably present in a concentration sufficient to block binding of the targeting molecule to the IL-4 receptor. The chimeric molecule thus specifically binds to the tumor cell. In a preferred embodiment, particularly where the blocker is a molecule that also occurs endogenously (*e.g.*, IL-4) the blocker is present in a concentration greater than that found in the environment in which the tumor cells and/or healthy (non-tumorous) cells normally occur. Any of the IL-4R blockers described herein are suitable. Any of the targeting molecules described herein are suitable targeting molecules in the chimeric molecule and any of the cytotoxic molecules described herein are suitable effector molecules. Preferred IL-13R-directed

chimera/blocker combinations include, but are not limited to IL-13-PE38QQR or IL-13-PE4E and [Y124D]hIL4 or [R121D, Y124D]hIL4. Particularly preferred targets are tumor cells that overexpress IL-13 receptors. Such tumor cells include, but are not limited to renal cell carcinoma cells, brain tumor cells (*e.g.*, glioma cells, medulloblastoma cells, *etc.*), and Kaposi's sarcoma cells. The tumor cell growth that is inhibited can be tumor cell growth in a human. The contacting step may comprise administering the chimeric molecule to a human intravenously, into a body cavity, or into a lumen or an organ..

In still another embodiment, this invention provides a method of detecting the presence, absence, size, or number of tumor cells. The method involves contacting the tumor cell(s) with a chimeric molecule comprising a targeting molecule that specifically binds a human IL-13 receptor; and a detectable label, and detecting the presence, absence, or quantity of the detectable label. The contacting is in the presence of a blocker of an interleukin receptor (IL-4R) and the blocker is present in a concentration sufficient to block binding of the targeting molecule to an IL-4 receptor. In a preferred embodiment, particularly where the blocker is a molecule that also occurs endogenously (*e.g.*, IL-4) the blocker is present in a concentration greater than that found in the environment in which the tumor cells and/or healthy (non-tumorous) cells normally occur. Suitable blockers and targeting molecules include any of the blockers and targeting described herein. Detectable labels include, but are not limited to those discussed herein.

In still yet another embodiment, this invention provides a pharmacological composition. The composition includes a pharmaceutically acceptable carrier, a chimeric molecule comprising an effector molecule attached to a targeting molecule that specifically binds to an IL-13 receptor, and a blocker of an interleukin receptor (IL-4R). Any of the chimeric molecules, more preferably the cytotoxic chimeras and chimeras in which the effector is a detectable label, and most preferably the cytotoxic chimeras, described herein are suitable. The blocker can include, but is not limited to, any of the blockers described herein.

Definitions

The term "specifically deliver" as used herein refers to the preferential association of a molecule with a cell or tissue bearing a particular target molecule or marker and not to cells or tissues lacking that target molecule or expressing that target molecule at low levels. It is, of course, recognized that a certain degree of non-specific interaction may occur between a molecule and a non-target cell or tissue. Nevertheless, specific delivery, may be distinguished as mediated through specific recognition of the target molecule. Typically specific delivery results in a much stronger association between the delivered molecule and cells bearing the target molecule than between the delivered molecule and cells lacking the target molecule. Specific delivery typically results in greater than 2 fold, preferably greater than 5 fold, more preferably greater than 10 fold and most preferably greater than 100 fold increase in amount of delivered molecule (per unit time) to a cell or tissue bearing the target molecule as compared to a cell or tissue lacking the target molecule or marker.

The term "blocker" when used with reference to an IL-4 receptor refers to a substance that specifically binds to an IL-4 receptor, or component thereof, and reduces or prevents binding of that receptor by another different substance (*e.g.*, an IL-13 based chimeric molecule). Because the blocker competes with the native ligand (IL-4) for the IL-4 receptor it is also referred to as an IL-4 competitor. Moreover, since most preferred blockers do not activate the IL-4 receptor, the preferred blocker is an "IL-4 antagonist" or a "competitive antagonist" of IL-4. One of skill in the art will appreciate that a blocker, to be effective, need not eliminate all binding to the "blocked" receptor but rather a simple reduction in binding of other molecules to the subject receptor is sufficient. The effect of such blocking is to make the receptor, on average, generally less available for binding to moieties other than the blocking agent.

The term "residue" as used herein refers to an amino acid that is incorporated into a polypeptide. The amino acid may be a naturally occurring amino acid and, unless otherwise limited, may encompass known analogs of natural amino acids that can function in a similar manner as naturally occurring amino acids.

A "fusion protein" refers to a polypeptide formed by the joining of two or more polypeptides through a peptide bond formed between the amino terminus of one

polypeptide and the carboxyl terminus of another polypeptide. The fusion protein may be formed by the chemical coupling of the constituent polypeptides or it may be expressed as a single polypeptide from nucleic acid sequence encoding the single contiguous fusion protein. A single chain fusion protein is a fusion protein having a single contiguous polypeptide backbone.

A "spacer" as used herein refers to a peptide that joins the proteins comprising a fusion protein. Generally a spacer has no specific biological activity other than to join the proteins or to preserve some minimum distance or other spatial relationship between them. However, the constituent amino acids of a spacer may be selected to influence some property of the molecule such as the folding, net charge, or hydrophobicity of the molecule. A spacer can also be an organic (non-peptide) molecule that serves the same purpose as the peptide spacer.

A "ligand", as used herein, refers generally to all molecules capable of reacting with or otherwise recognizing or binding to a receptor on a target cell. Specifically, examples of ligands include, but are not limited to, antibodies, lymphokines, cytokines, receptor proteins such as CD4 and CD8, solubilized receptor proteins such as soluble CD4, hormones, growth factors, and the like which specifically bind desired target cells.

The term "cpIL-13" is used to designate a circularly permuted (cp) IL-13. Circular permutation is functionally equivalent to taking a straight-chain molecule, fusing the ends (directly or through a linker) to form a circular molecule, and then cutting the circular molecule at a different location to form a new straight chain molecule having different termini.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the cytotoxic activity of hIL13-PE38QQR on established glioma cell lines and human glioma (G2) explant cells and failure to inhibit this cytotoxicity by hIL4. hIL4 was added at a concentration of 1.0 $\mu\text{g/ml}$. Three different batches of rhIL-4 showed the same effect. The dashed line shows 50% of the difference between the background and control MTS conversion that was recorded at $A_{490\text{ nm}}$.

Figure 2 shows the cytotoxicity of hIL-4-PE38QQR on glioma cells and blocking of this cytotoxicity by hIL-13. Human IL-13 was added at a concentration of 1.0 $\mu\text{g/ml}$. The dashed line shows 50% of the difference between the background and control MTS conversion that was recorded at A_{490} nm.

5 Figure 3 shows the cytotoxicity of hIL-4-PE4E on glioma cells and blocking of this cytotoxicity by hIL-13. Human IL-13 was added at a concentration of 1.0 $\mu\text{g/ml}$. The dashed line shows 50% of the difference between the background and control MTS conversion that was recorded at A_{490} nm.

10 Figure 4 shows that hIL-13 and hIL-4 do not inhibit proliferation of the U-373 MG and human glioma G2 explant cells. Data represent, in most cases, the average of quadruplicates. The dashed line shows 50% of the difference between the background and control MTS conversion that was recorded at A_{490} nm.

15 Figures 5A and 5B illustrate a competitive binding assay on A-172 glioblastoma cells. Data are expressed as a percentage of total ^{125}I -hIL-13 binding to cells (Figure 5A) and as a Scatchard plot (Figure 5B). The points are the average of two determinations. Similar data were obtained on three other established glioma cell lines.

20 Figures 6A and 6B illustrate a competitive binding assay on human glioma G2 explant cells. Data are expressed as a percentage of total ^{125}I -hIL-13 binding to cells (Figure 6A) and as a Scatchard plot (Figure 6B). The points are the average of two determinations. Similar data were obtained on three other established glioma cell lines.

25 Figures 7A and 7B show cross-competition between hIL-13 and hIL-4 for the binding sites of labeled interleukins on glioma cells. A-172 glioblastoma cells (1×10^6) were incubated with 200 pM ^{125}I -hIL-13 (Figure 7A) or ^{125}I -hIL-4 (Figure 7B) with or without increasing concentrations (up to 100 nM) of unlabeled hIL-13 or hIL-4. Bound radioactivity was determined as described in Example 13. Data are presented as a mean of % total binding of cells incubated with radiolabeled interleukins only. total of ^{125}I -hIL-13 bound to A-172 cells was 8699 ± 11 (cpm \pm SD) and total bound ^{125}I -hIL-4 was 5789 ± 185 (cpm \pm SD). The experiments were performed in duplicates. Bars, SD shown when larger than symbol.

30 Figure 8 shows competition of hIL-13 for the binding sites of labeled hIL-4 on CTLL-2 cells transfected with the human 140 kDa IL-4 receptor (CTLL-2^{hIL4R}).

CTLL-2^{hIL4R} cells were incubated with 200 mP of ¹²⁵I-hIL-4 with or without excess hIL-13 or hIL-4. The results are expressed as % of total binding. Total ¹²⁵I-hIL-4 bound to cells was 4412 ± 344 (cpm ± SD). The experiments were done in duplicates and bars represent SD when larger than symbols.

5

DETAILED DESCRIPTION

I. Chimeric Molecules Targeted to the IL-13 Receptor.

This invention provides compositions and methods for specifically delivering an effector molecule to a tumor cell. This method involves the use of chimeric molecules in combination with a blocking agent to specifically target the tumor cells while sparing normal (healthy) cells. The chimeric molecule comprises a targeting molecule attached to an effector molecule. In a particularly preferred embodiment, the targeting molecule specifically recognizes and binds to the IL-13 receptor, while the blocking agent (blocker) specifically recognizes and binds to the IL-4 receptor.

The improved specific targeting of this invention is premised, in part, on two discoveries: The first discovery was that tumors including, but not limited to, renal cell carcinomas (RCCs), Kaposi's sarcoma (KS), and brain tumors, overexpress IL-13 receptors at extremely high levels. While the IL-13 receptors (IL-13R) are overexpressed on tumor cells, expression of these receptors on other cells (*e.g.* monocytes, B cells, and T cells) appears negligible. Thus, by specifically targeting the IL-13 receptor, the present invention provides chimeric molecules that are specifically directed to solid tumors while minimizing targeting of other cells or tissues.

The second discovery was that, although IL-4 and IL-13 appear to share a common receptors in healthy cells (part of which is the 140 kDa subunit described herein), transformed cells express an IL-13 receptor that is not shared with IL-4; that is, it does not involve the 140 kDa subunit. Administration of an IL-4 receptor blocker in conjunction with an IL-13 receptor directed chimeric molecule will block binding of that molecule to normal cells bearing IL-4 receptors and/or the shared (140 kDa subunit) without inhibiting binding of the molecule to cancer cells.

Thus, in a preferred embodiment, this invention provides a method of specifically delivering an effector molecule to a tumor cell bearing an IL-13 receptor. The method involves the steps of providing a chimeric molecule comprising an effector

molecule attached to a targeting molecule that specifically binds to an IL-13 receptor; and contacting the tumor cell with the chimeric molecule in the presence of a blocker of an interleukin receptor (IL-4R). The blocker is preferably provided in a concentration sufficient to block binding of the targeting molecule to an IL-4 receptor.

5 The effector component of the chimeric molecule can be any of a wide number of effectors well known to those of skill in the art. These include, but are not limited to a cytotoxin a label, a radionuclide, a drug, a prodrug, a prodrug conversion enzyme, a liposome, a ligand, an antisense molecule, an expression cassette, and an antibody. In one particularly preferred embodiment, the effector is a cytotoxin and the
10 method provides a means to impair the growth of tumor cells (or tumors). The cytotoxin may be a native or modified cytotoxin such as *Pseudomonas* exotoxin (PE), *Diphtheria* toxin (DT), ricin, abrin, pokeweed antiviral protein, and the like.

 The chimeric cytotoxin is administered to an organism containing tumor cells either in conjunction with or after administration of an IL-4 receptor blocker. The
15 blocker prevents the chimeric toxin from binding to IL-4 receptors which are numerous on healthy cells leaving the chimeric cytotoxin free to contact IL-13 receptor expressing tumor cells. The targeting molecule component of the chimeric molecule specifically binds to the overexpressed IL-13 receptors on the tumor cells. Once bound to the IL-13 receptor on the cell surface, the cytotoxic effector molecule mediates internalization into
20 the cell where the cytotoxin inhibits cellular growth or kills the cell. Alternatively, the "cytotoxin" modifies the cell so that it is more susceptible to cytotoxic agents (*e.g.*, radiotherapy or chemotherapy).

 The use of chimeric molecules comprising a targeting moiety joined to a cytotoxic effector molecules to target and kill tumor cells is known in the prior art. For
25 example, chimeric fusion proteins which include interleukin 4 (IL-4) or transforming growth factor (TGF α) fused to *Pseudomonas* exotoxin (PE) or interleukin 2 (IL-2) fused to Diphtheria toxin (DT) have been tested for their ability to specifically target and kill cancer cells (Pastan *et al.*, *Ann. Rev. Biochem.*, 61: 331-354 (1992)).

 Although the use of cytotoxic chimeric molecules is known in the prior
30 art, it is believed the use of an IL-4 receptor blocker in conjunction with a cytotoxin has never been described. Chimeric IL-4-cytotoxin molecules are known in the prior art.

and IL-4 shows some sequence similarity to IL-13. Moreover, the IL-4 and IL-13 receptors share a component and are reciprocally inhibited by their native ligands in normal cells. Thus, it was an unexpected discovery of this invention that tumor cells express an IL-13 receptor that is apparently decoupled from the IL-4 receptor and that this IL-13 receptor is consequently not blocked by IL-4 or other agents that bind to the IL-4 receptor (*e.g.*, [Y124D]hIL4).

In addition, it was also a surprising discovery of this invention that cytotoxins targeted by a moiety specific to the IL-13 receptor show significantly increased efficacy as compared to IL-4 receptor directed cytotoxins. Without being bound to a particular theory, it is believed that the improved efficacy of the IL-13 chimeras of the present invention is due to at least three factors.

First, IL-13 receptors are expressed at much lower levels, if at all on non-tumor cells (*e.g.* monocytes, T cells, B cells). Thus cytotoxins directed to IL-13 receptors show reduced binding and subsequent killing of healthy cells and tissues as compared to other cytotoxins.

Second, the receptor component that specifically binds IL-13 appears to be expressed at significantly higher levels on solid tumors than the receptor component that binds IL-4. Thus, tumor cells bind higher levels of cytotoxic chimeric molecules directed against IL-13 receptors than cytotoxic chimeric molecules directed against IL-4 receptors.

Finally, IL-4 receptors are up-regulated when immune system cells (*e.g.* T-cells) are activated. This results in healthy cells, for example T-cells and B-cells, showing greater susceptibility to IL-4 receptor directed cytotoxins. Thus, the induction of an immune response (as against a cancer), results in greater susceptibility of cells of the immune system to the therapeutic agent. In contrast, IL-13 receptors have not been shown to be up-regulated in activated T cells. Thus IL-13 receptor targeted cytotoxins have no greater effect on activated T cells and thereby minimize adverse effects of the therapeutic composition on cells of the immune system. Moreover, even when the immune system is upregulated, the ability to specifically block immune cells using IL-4 receptor blockers in conjunction with the IL-13 receptor directed chimeric toxins results in even greater efficacy of these toxins with greater sparing of normal (healthy) cells.

In another embodiment, this invention also provides for compositions and methods for detecting the presence or absence of tumor cells. These methods involve providing a chimeric molecule comprising an effector molecule, that is a detectable label attached to a targeting molecule that specifically binds an IL-13 receptor. The chimeric molecule is contacted to the tumor cells in the presence of an IL-4 receptor blocker. The blocker reduces or eliminates binding of the chimeric molecule to IL-4 receptors leaving the IL-13 receptor targeting moiety free to specifically bind the chimeric molecule to tumor cells which are then marked by their association with the detectable label. Subsequent detection of the cell-associated label indicates the presence of a tumor cell.

In yet another embodiment, the effector molecule may be another specific binding moiety such as an antibody, a growth factor, or a ligand. The chimeric molecule, especially in the presence of an IL-4 receptor blocker, will then act as a highly specific bifunctional linker. This linker may act to bind and enhance the interaction between cells or cellular components to which the fusion protein binds. Thus, for example, where the "targeting" component of the chimeric molecule comprises a polypeptide that specifically binds to an IL-13 receptor and the "effector" component is an antibody or antibody fragment (*e.g.* an Fv fragment of an antibody), the targeting component specifically binds cancer cells, while the effector component binds receptors (*e.g.*, IL-2 receptors) on the surface of immune cells. The chimeric molecule may thus act to enhance and direct an immune response toward target cancer cells.

In still yet another embodiment the effector molecule may be a pharmacological agent (*e.g.* a drug or a prodrug) or a vehicle containing a pharmacological agent. This is particularly suitable where it is merely desired to invoke a non-lethal biological response. Thus the moiety that specifically binds to an IL-13 receptor may be conjugated to a drug such as vinblastine, doxorubicin or its derivatives, genistein (a tyrosine kinase inhibitor), an antisense molecule, and other pharmacological agents known to those of skill in the art, thereby specifically targeting the pharmacological agent to tumor cells overexpressing IL-13 receptors.

Alternatively, the targeting molecule may be bound to a vehicle containing the therapeutic composition. Such vehicles include, but are not limited to liposomes, micelles, various synthetic beads, and the like.

One of skill in the art will appreciate that the chimeric molecules of the present invention may include multiple targeting moieties bound to a single effector or conversely, multiple effector molecules bound to a single targeting moiety. In still other embodiment, the chimeric molecules may include both multiple targeting moieties and multiple effector molecules. Thus, for example, this invention provides for "dual targeted" cytotoxic chimeric molecules in which targeting molecule that specifically binds to IL-13 is attached to a cytotoxic molecule and another molecule (*e.g.* an antibody, or another ligand) is attached to the other terminus of the toxin. Such a dual-targeted cytotoxin might comprise an IL-13 substituted for domain Ia at the amino terminus of a PE and anti-TAC(Fv) inserted in domain III, between amino acid 604 and 609. Other antibodies may also be suitable.

II. The Targeting Molecule.

In a preferred embodiment, the targeting molecule is a molecule that specifically binds to the IL-13 receptor. The term "specifically binds", as used herein, when referring to a protein or polypeptide, refers to a binding reaction which is determinative of the presence of the protein or polypeptide in a heterogeneous population of proteins and other biologics. Thus, under designated conditions (*e.g.* immunoassay conditions in the case of an antibody), the specified ligand or antibody binds to its particular "target" protein (*e.g.* an IL-13 receptor protein) and does not bind in a significant amount to other proteins present in the sample or to other proteins to which the ligand or antibody may come in contact in an organism.

A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with an IL-13 receptor protein. For example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity.

Similarly, assay formats for detecting specific binding of ligands (*e.g.* IL-13, cpIL-13) with their respective receptors are also well known in the art. Example 1

provides a detailed protocol for assessing specific binding of labeled IL-13 by an IL-13 receptor.

The IL-13 receptor is a cell surface receptor that specifically binds IL-13 and mediates a variety of physiological responses in various cell types as described below in the description of IL-13. The IL-13 receptor may be identified by contacting a cell or other sample with labeled IL-13 and detecting the amount of specific binding of IL-13 according to methods well known to those of skill in the art. Detection of IL-13 receptors by labeled IL-13 binding is described in detail in Example 1.

Alternatively, an anti-IL-13 receptor antibody may also be used to identify IL-13 receptors. The antibody will specifically bind to the IL-13 receptor and this binding may be detected either through detection of a conjugated label or through detection of a labeled second antibody that binds the anti-IL-13 receptor antibody.

In a preferred embodiment, the moiety utilized to specifically target the IL-13 receptor is either an antibody that specifically binds the IL-13 receptor (an anti-IL-13R antibody) or a ligand, such as IL-13 or cpIL-13, that specifically binds to the receptor. Such ligands may include other molecules selected, for example from peptide libraries, or IL-13 mimetics designed to bind the IL-13 receptor.

A) IL-13.

Interleukin-13 (IL-13) is a pleiotropic cytokine that is recognized to share many of the properties of IL-4. IL-13 has approximately 30% sequence identity with IL-4 and exhibits IL-4-like activities on monocytes/macrophages and human B cells (Minty *et al.*, *Nature*, 362: 248 (1993), McKenzie *et al.* *Proc. Natl. Acad. Sci. USA*, 90: 3735 (1987)). In particular, IL-13 appears to be a potent regulator of inflammatory and immune responses. Like IL-4, IL-13 can up-regulate the monocyte/macrophage expression of CD23 and MHC class I and class II antigens, down-regulate the expression of Fcγ, and inhibit antibody-dependent cytotoxicity. IL-13 can also inhibit nitric oxide production as well as the expression of pro-inflammatory cytokines (*e.g.* IL-1, IL-6, IL-8, IL-10 and IL-12) and chemokines (MIP-1, MCP), but enhance the production of IL-1 (Minty *supra.*; McKenzie *et al.*, *supra.*; Zurawski *et al.* *Immunol. Today*, 15: 19 (1994); de Waal Malefyt *et al.* *J. Immunol.*, 150: 180A (1993); de Waal Malefyt *et al.*

J. Immunol., 151: 6370 (1993); Doherty *et al. J. Immunol.*, 151: 7151 (1993); and Minty *et al. Eur. Cytokine Nerv.*, 4: 99 (1993)).

Recombinant IL-13 is commercially available from a number of sources (see, e.g. R & D Systems, Minneapolis, Minnesota, USA, and Sanofi Bio-Industries, Inc., Tervose, Pennsylvania, USA). Alternatively, a gene or a cDNA encoding IL-13 may be cloned into a plasmid or other expression vector and expressed in any of a number of expression systems according to methods well known to those of skill in the art. Methods of cloning and expressing IL-13 and the nucleic acid sequence for IL-13 are well known (see, for example, Minty *et al. (1993) supra.* and McKenzie (1993), *supra*). In addition, the expression of IL-13 as a component of a chimeric molecule is detailed in Example 4.

One of skill in the art will appreciate that analogues or fragments of IL-13 bearing will also specifically bind to the IL-13 receptor. For example, conservative substitutions of residues (e.g., a serine for an alanine or an aspartic acid for a glutamic acid) comprising native IL-13 will provide IL-13 analogues that also specifically bind to the IL-13 receptor. Thus, the term "IL-13", when used in reference to a targeting molecule, also includes fragments, analogues or peptide mimetics of IL-13 that also specifically bind to the IL-13 receptor.

B) Anti-IL-13 receptor antibodies.

i) The antibodies.

One of skill will recognize that other molecules besides IL-13 will specifically bind to IL-13 receptors. Polyclonal and monoclonal antibodies directed against IL-13 receptors provide particularly suitable targeting molecules in the chimeric molecules of this invention. The term "antibody", as used herein, includes various forms of modified or altered antibodies, such as an intact immunoglobulin, various fragments such as an Fv fragment, an Fv fragment containing only the light and heavy chain variable regions, an Fv fragment linked by a disulfide bond (Brinkmann, *et al. Proc. Natl. Acad. Sci. USA*, 90: 547-551 (1993)), an Fab or (Fab)'₂ fragment containing the variable regions and parts of the constant regions (see, e.g., Debinski *et al., Clin. Cancer. Res.*, 1: 1015-1022 (1995), a single-chain antibody and the like (Bird *et al.*,

Science 242: 424-426 (1988); Huston *et al.*, *Proc. Nat. Acad. Sci. USA* 85: 5879-5883 (1988)). The antibody may be of animal (especially mouse or rat) or human origin or may be chimeric (Morrison *et al.*, *Proc Nat. Acad. Sci. USA* 81: 6851-6855 (1984)) or humanized (Jones *et al.*, *Nature* 321: 522-525 (1986), and published UK patent application #8707252). Methods of producing antibodies suitable for use in the present invention are well known to those skilled in the art and can be found described in such publications as Harlow & Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory (1988), and Asai, *Methods in Cell Biology Vol. 37: Antibodies in Cell Biology*, Academic Press, Inc. N.Y. (1993).

Antibodies that specifically bind the IL-13 receptor may be produced by a number of means well known to those of skill in the art. Generally, this involves using an antigenic component of the IL-13 receptor as an antigen to induce the production of antibodies in an organism (*e.g.* a sheep, mouse, rabbit, *etc.*). One of skill in the art will recognize that there are numerous methods of isolating all or components of the IL-13 receptor for use as an antigen. For example, IL-13 receptors may be isolated by cross-linking the receptor to a labeled IL-13 by the exposure to 2 mM disuccinimidyl suberate (DSS). The labeled receptor may then be isolated according to routine methods and the isolated receptor may be used as an antigen to raise anti-IL-13 receptor antibodies as described below. Cross-linking and isolation of components of the IL-13 receptor is described in Example 3.

In a preferred embodiment, however, IL-13 receptors may be isolated by means of affinity chromatography. It was a surprising discovery of the present invention that solid tumor cells overexpress IL-13 receptors. This discovery of cells overexpressing IL-13 receptor greatly simplifies the receptor isolation. Generally, approximately, 100 million renal carcinoma cells, may be solubilized in detergent with protease inhibitors according to standard methods. The resulting lysate is then run through an affinity column bearing IL-13. The receptor binds to the IL-13 in the column thereby effecting an isolation from the lysate. The column is then eluted with a low pH buffer to dissociate the IL-13 ligand from the IL-13 receptor resulting in isolated receptor. The isolated receptor may then be used as an antigen to raise anti-IL-13 receptor antibodies.

ii) Antibody production.

Methods of producing polyclonal antibodies are known to those of skill in the art. In brief, an immunogen, preferably an isolated IL-13 receptor or receptor epitope is mixed with an adjuvant and animals are immunized with the mixture. The animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of reactivity to the polypeptide of interest. When appropriately high titers of antibody to the immunogen are obtained, blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the polypeptide is performed where desired. *See, e.g.,* Coligan (1991) *Current Protocols in Immunology* Wiley/Greene, NY; and Harlow and Lane (1989) *Antibodies: A Laboratory Manual* Cold Spring Harbor Press, NY).

Monoclonal antibodies may be obtained by various techniques familiar to those skilled in the art. Description of techniques for preparing such monoclonal antibodies may be found in, *e.g.,* Stites *et al.* (eds.) *Basic and Clinical Immunology* (4th ed.) Lange Medical Publications, Los Altos, CA, and references cited therein; Harlow and Lane (1988) *Antibodies: A Laboratory Manual* CSH Press; Goding (1986) *Monoclonal Antibodies: Principles and Practice* (2d ed.) Academic Press, New York, NY; and particularly in Kohler and Milstein (1975) *Nature* 256: 495-497, which discusses one method of generating monoclonal antibodies.

Summarized briefly, this method involves injecting an animal with an immunogen. The animal is then sacrificed and cells taken from its spleen, which are then fused with myeloma cells (*See, Kohler and Milstein (1976) Eur. J. Immunol. 6: 511-519*). The result is a hybrid cell or "hybridoma" that is capable of proliferation *in vitro*, and producing antibodies against the "given" immunogen.

Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells is enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host. Alternatively, one may isolate DNA sequences which encode a monoclonal antibody or a binding fragment thereof by screening a DNA library from human B cells according to the general

protocol outlined by Huse *et al.* (1989) *Science* 246: 1275-1281. In this manner, the individual antibody species obtained are the products of immortalized and cloned single B cells from the immune animal generated in response to a specific site recognized on the immunogenic substance.

5 Other suitable techniques involve selection of libraries of antibodies in phage or similar vectors. See, Huse *et al.* *Science* 246: 1275-1281 (1989); and Ward, *et al.* *Nature* 341: 544-546 (1989). In general suitable monoclonal antibodies will usually bind their target epitope with at least a K_D of about 1 mM, more usually at least about 300 μ M, and most preferably at least about 0.1 μ M or better.

10 One of skill will appreciate that the IL-13R targeting antibodies and the IL-4R blocking antibodies of this invention can also include humanized (chimeric) or human antibodies.

i) Humanized (chimeric) antibodies.

Humanized (chimeric) antibodies are immunoglobulin molecules
15 comprising a human and non-human portion. More specifically, the antigen combining region (or variable region) of a humanized chimeric antibody is derived from a non-human source (*e.g.*, murine) and the constant region of the chimeric antibody (which confers biological effector function to the immunoglobulin) is derived from a human source. The humanized chimeric antibody should have the antigen binding (*e.g.*,
20 anti-IL-4R or anti-IL-13R) specificity of the non-human antibody molecule and the effector function conferred by the human antibody molecule. A large number of methods of generating chimeric antibodies are well known to those of skill in the art (*see, e.g.*, U.S. Patent Nos: 5,502,167, 5,500,362, 5,491,088, 5,482,856, 5,472,693, 5,354,847, 5,292,867, 5,231,026, 5,204,244, 5,202,238, 5,169,939, 5,081,235, 5,075,431, and
25 4,975,369).

 In general, the procedures used to produce these chimeric antibodies consist
of the following steps (the order of some steps may be interchanged): (a) identifying and cloning the correct gene segment encoding the antigen binding portion of the antibody
30 molecule; this gene segment (known as the VDJ, variable, diversity and joining regions for heavy chains or VJ, variable, joining regions for light chains (or simply as the V or

Variable region) may be in either the cDNA or genomic form; (b) cloning the gene segments encoding the constant region or desired part thereof; (c) ligating the variable region with the constant region so that the complete chimeric antibody is encoded in a transcribable and translatable form; (d) ligating this construct into a vector containing a selectable marker and gene control regions such as promoters, enhancers and poly(A) addition signals; (e) amplifying this construct in a host cell (*e.g.*, bacteria); (f) introducing the DNA into eukaryotic cells (transfection) most often mammalian lymphocytes;

Antibodies of several distinct antigen binding specificities have been manipulated by these protocols to produce chimeric proteins (*e.g.*, anti-TNP: Boulianne *et al.* (1984) *Nature*, 312: 643; and anti-tumor antigens: Sahagan *et al.* (1986) *J. Immunol.*, 137: 1066). Likewise several different effector functions have been achieved by linking new sequences to those encoding the antigen binding region. Some of these include enzymes (Neuberger *et al.* (1984) *Nature* 312: 604), immunoglobulin constant regions from another species and constant regions of another immunoglobulin chain (Sharon *et al.* (1984) *Nature* 309: 364; Tan *et al.*, (1985) *J. Immunol.* 135: 3565-3567). Detailed methods for preparation of chimeric (humanized) antibodies can be found in U.S. Patent 5,482,856.

b) Human antibodies.

In another embodiment, this invention provides for fully human anti-IL-4R antibodies. Human antibodies consist entirely of characteristically human polypeptide sequences. The human antibodies (*e.g.*, anti-IL-4R) used in this invention can be produced in using a wide variety of methods (*see, e.g.*, Larrick *et al.*, U.S. Pat. No. 5,001,065, for review).

In one preferred embodiment, the human antibodies of the present invention are usually produced initially in trioma cells. Genes encoding the antibodies are then cloned and expressed in other cells, particularly, nonhuman mammalian cells.

The general approach for producing human antibodies by trioma technology has been described by Ostberg *et al.* (1983), *Hybridoma* 2: 361-367, Ostberg, U.S. Pat.No. 4,634,664, and Engelman *et al.*, U.S. Pat. No. 4,634,666. The

antibody-producing cell lines obtained by this method are called triomas because they are descended from three cells; two human and one mouse. Triomas have been found to produce antibody more stably than ordinary hybridomas made from human cells.

In another approach, mouse-human hybridomas which produces
5 human anti-IL4R antibodies are prepared (*see, e.g.*, U.S. Patent No: 5,506,132). Other approaches include immunization of murines transformed to express human immunoglobulin genes, and phage display screening (Vaughan *et al. supra.*).

C) Circularly permuted IL-13.

10 In another embodiment, the targeting moiety can be a circularly permuted IL-13 (cpIL-13). Circular permutation is functionally equivalent to taking a straight-chain molecule, fusing the ends (directly or through a linker) to form a circular molecule, and then cutting the circular molecule at a different location to form a new straight chain molecule with different termini (*see, e.g.*, Goldenberg, *et al. J. Mol.*
15 *Biol.*, 165: 407-413 (1983) and Pan *et al. Gene* 125: 111-114 (1993)). Circular permutation thus has the effect of essentially preserving the sequence and identity of the amino acids of a protein while generating new termini at different locations.

Circular permutation of IL-13 provides a means by which the native IL-13 protein may be altered to produce new carboxyl and amino termini without diminishing
20 the specificity and binding affinity of the altered first protein relative to its native form. With new termini located away from the active (binding) site, it is possible to incorporate the circularly permuted IL-13 into a fusion protein with a reduced, or no diminution, of IL-13 binding specificity and/or avidity.

It will be appreciated that while circular permutation is described in terms
25 of linking the two ends of a protein and then cutting the circularized protein these steps are not actually required to create the end product. A protein can be synthesized *de novo* with the sequence corresponding to a circular permutation of the native protein. Thus, the term "circularly permuted IL-13 (cpIL-13)" refers to all IL-13 proteins having a sequence corresponding to a circular permutation of a native IL-13 protein regardless
30 of how they are constructed.

Generally, however, a permutation that retains or improves the binding specificity and/or avidity (as compared to the native IL-13) is preferred. If the new termini interrupt a critical region of the native protein, binding specificity and avidity may be lost. Similarly, if linking the original termini destroys IL-13 binding specificity and avidity then no circular permutation is suitable. Thus, there are two requirements for the creation of an active circularly permuted protein: 1) The termini in the native protein must be favorably located so that creation of a linkage does not destroy binding specificity and/or avidity; and 2) There must exist an "opening site" where new termini can be formed without disrupting a region critical for protein folding and desired binding activity (*see, e.g., Thorton et al. J. Mol. Biol., 167: 443-460 (1983)*). This invention establishes that IL-13 meets these criteria and provides for circularly permuted IL-13 that having improved binding characteristics.

When circularly permuting IL-13, it is desirable to use a linker that preserves the spacing between the termini comparable to the unpermuted or native molecule. Generally linkers are either hetero- or homo-bifunctional molecules that contain two reactive sites that may each form a covalent bond with the carboxyl and the amino terminal amino acids respectively. Suitable linkers are well known to those of skill in the art and include, but are not limited to, straight or branched-chain carbon linkers, heterocyclic carbon linkers, or peptide linkers. The most common and simple example is a peptide linker that typically consists of several amino acids joined through peptide bonds to the termini of the native protein. The linkers may be joined to the terminal amino acids through their side groups (*e.g., through a disulfide linkage to cysteine*). However, in a preferred embodiment, the linkers will be joined to the alpha carbon amino and carboxyl groups of the terminal amino acids.

Functional groups capable of forming covalent bonds with the amino and carboxyl terminal amino acids are well known to those of skill in the art. For example, functional groups capable of binding the terminal amino group include anhydrides, carbodimides, acid chlorides, activated esters and the like. Similarly, functional groups capable of forming covalent linkages with the terminal carboxyl include amines, alcohols, and the like. In a preferred embodiment, the linker will itself be a peptide and will be joined to the protein termini by peptide bonds. A preferred linker for the

circular permutation of IL-13 is two glycines (Gly)₂, followed by a serine (Ser) followed by two glycines (Gly)₂.

In a preferred embodiment, circular permutation of IL-13 involves creating an opening such that the formation of new termini does not interrupt secondary structure crucial to the formation of a structure that specifically binds the IL-13 receptor. Even if the three-dimensional structure is compatible with joining the termini, it is conceivable that the kinetics and thermodynamics of folding would be greatly altered by circular permutation if the cleavage separates residues that participate in short range interactions that are crucial for the folding mechanism or the stability of the native state. Goldenberg, *Protein Eng.*, 7: 493-495 (1989). Thus, the choice of a cleavage site can be important to the protein's binding specificity and/or avidity.

The selection of an opening site in IL-13 may be determined by a number of factors. Preferred opening sites will be located in regions that do not show a highly regular three-dimensional structure. Thus, it is preferred that cleavage sites be selected in regions of the protein that do not show secondary structure such as alpha helices, pleated sheets, $\alpha\beta$ barrel structures, and the like.

Methods of identifying regions of particular secondary structure of IL-13 based on amino acid sequence are widely known to those of skill in the art. See, for example, Cohen *et al.*, *Science*, 263: 488-489 (1994). Numerous programs exist that predict protein folding based on sequence data. Some of the more widely known software packages include MatchMaker (Tripos Associates, St. Louis, Missouri, USA), FASMAN from GCG (Genetics Computer Group), PHD (European Molecular Biology Laboratory, Heidelberg, Germany) and the like. In addition, the amino acid sequence of IL-13 is well known and the protein has been extensively characterized (*see, e.g.*, WO 94/04680).

Alternatively, where the substitution of certain amino acids or the modification of the side chains of certain amino acids does not change the activity of a protein, it is expected that the modified amino acids are not critical to the protein's activity. Thus, amino acids that are either known to be susceptible to modification or are actually modified *in vivo* are potentially good candidates for cleavage sites.

Where the protein is a member of a family of related proteins, one may infer that the highly conserved sequences are critical for biological activity, while the variable regions are not. Preferred cleavage sites are then selected in regions of the protein that do not show highly conserved sequence identity between various members of the protein family. Alternatively, if a cleavage site is identified in a conserved region of a protein, that same region provides a good candidate for cleavage sites in a homologous protein.

Methods of determining sequence identity are well known to those of skill in the art. Sequence comparisons between two (or more) polynucleotides or polypeptides are typically performed by comparing sequences of the two sequences over a "comparison window" to identify and compare local regions of sequence similarity. Since the goal is to identify very local sequence regions that are not conserved, the comparison window will be selected to be rather small. A "comparison window", as used herein, refers to a segment of at least about 5 contiguous positions, usually about 10 to about 50, more usually about 15 to about 40 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith *et al.* *Adv. Appl. Math.* 2: 482 (1981), by the homology alignment algorithm of Needleman *et al.*, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson *et al.*, *Proc. Natl. Acad. Sci. USA*, 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by inspection.

A preferred opening site in IL-13 is just prior to Met-44 of hIL-13, just at the beginning of the putative second alpha-helix resulting in a circularly permuted IL-13 having a methionine at position 44 of the native IL-13 at the amino terminus of the cpIL-13 and the Glycine at position 43 of the native IL-13 at the new carboxyl terminus of the cpIL-13. This carboxyl terminus can be joined to a second protein directly or through a spacer.

Circularly permuted IL-13 may be made by a number of means known to those of skill in the art. These include chemical synthesis, modification of existing proteins, and expression of circularly permuted proteins using recombinant DNA methodology.

5 The circularly permuted IL-13 may be synthesized using standard chemical peptide synthesis techniques as discussed below in section IV(B). If the linker is a peptide it may be incorporated during the synthesis. If the linker is not a peptide it may be coupled to the peptide after synthesis.

10 Alternatively, the circularly permuted IL-13 can be made by chemically modifying a native IL-13 (*e.g.* a native human IL-13). Generally, this requires reacting the IL-13 in the presence of the linker to form covalent bonds between the linker and the carboxyl and amino termini of the protein, thus forming a circular protein. New termini are then formed by cleaving the peptide bond joining amino acids at another location. This may be accomplished chemically or enzymatically using, for example, a peptidase.

15 If the cleavage reaction tends to hydrolyze more than one peptide bond, the reaction may be run briefly. Those molecules having more than one peptide bond cleaved will be shorter than the full length circularly permuted molecule and the latter may be isolated by any protein purification technique that selects by size (*e.g.*, by size exclusion chromatography or electrophoresis). Alternatively, various sites in the circular
20 protein may be protected from hydrolysis by chemical modification of the amino acid side chains which may interfere with enzyme binding, or by chemical blocking of the vulnerable groups participating in the peptide bond.

 In a preferred embodiment, the circularly permuted IL-13, or fusion proteins comprising the circularly permuted IL-13 will be synthesized using recombinant
25 DNA methodology. Generally this involves creating a DNA sequence that encodes the circularly permuted growth factor (or entire fusion protein containing the growth factor), placing the DNA in an expression cassette under the control of a particular promoter, expressing the protein in a host, isolating the expressed protein and, if required, renaturing the protein. Recombinant expression of the fusion proteins of this invention is
30 discussed in more detail below in section IV(B).

DNA encoding circularly permuted growth factors or fusion proteins comprising circularly permuted growth factors may be prepared by any suitable method, including, for example, cloning and restriction of appropriate sequences or direct chemical synthesis by methods as discussed below. Alternatively, subsequences may be
5 cloned and the appropriate subsequences cleaved using appropriate restriction enzymes. The fragments may then be ligated to produce the desired DNA sequence.

In a preferred embodiment, DNA encoding the circularly permuted growth factor may be produced using DNA amplification methods, for example polymerase chain reaction (PCR). First, the segments of the native DNA on either side
10 of the new terminus are amplified separately. The 5' end of the one amplified sequence encodes the peptide linker, while the 3' end of the other amplified sequence also encodes the peptide linker. Since the 5' end of the first fragment is complementary to the 3' end of the second fragment, the two fragments (after partial purification, *e.g.* on LMP agarose) can be used as an overlapping template in a third PCR reaction. The amplified
15 sequence will contain codons the segment on the carboxy side of the opening site (now forming the amino sequence), the linker, and the sequence on the amino side of the opening site (now forming the carboxyl sequence). The circularly permuted molecule may then be ligated into a plasmid and expressed as discussed below.

20 D) Modified IL-13.

One of skill in the art will appreciate that IL-13 can be modified in a variety of ways that do not destroy binding specificity and/or avidity and, in fact, may increase binding properties. Some modifications may be made to facilitate the cloning, expression, or incorporation of the circularly permuted growth factor into a fusion
25 protein. Such modifications are well known to those of skill in the art and include, for example, a methionine added at the amino terminus to provide an initiation site to a mature polypeptide, or additional amino acids placed on either terminus to create conveniently located restriction sites or termination codons.

One of skill will recognize that other modifications may be made. Thus,
30 for example, amino acid substitutions may be made that increase specificity or binding affinity of the circularly permuted protein, *etc.* Alternatively, non-essential regions of

the molecule may be shortened or eliminated entirely. Thus, where there are regions of the molecule that are not themselves involved in the activity of the molecule, they may be eliminated or replaced with shorter segments that merely serve to maintain the correct spatial relationships between the active components of the molecule.

5

E) Other targeting antibodies.

Where the chimeric molecule contains more than one targeting molecule (e.g. a dual-targeted cytotoxin), the molecule may contain targeting antibodies directed to tumor markers other than the overexpressed IL-13 receptor. A number of such antibodies are known and have even been converted to form suitable for incorporation into fusion proteins. These include anti-erbB2, B3, BR96, OVB3, anti-transferrin, Mik-
10 β 1 and PR1 (see Batra *et al.*, *Mol. Cell. Biol.*, 11: 2200-2205 (1991); Batra *et al.*, *Proc. Natl. Acad. Sci. USA*, 89: 5867-5871 (1992); Brinkmann, *et al. Proc. Natl. Acad. Sci. USA*, 88: 8616-8620 (1991); Brinkmann *et al.*, *Proc. Natl. Acad. Sci. USA*, 90: 547-551 (1993); Chaudhary *et al.*, *Proc. Natl. Acad. Sci. USA*, 87: 1066-1070 (1990); Friedman
15 *et al.*, *Cancer Res.* 53: 334-339 (1993); Kreitman *et al.*, *J. Immunol.*, 149: 2810-2815 (1992); Nicholls *et al.*, *J. Biol. Chem.*, 268: 5302-5308 (1993); and Wells, *et al.*, *Cancer Res.*, 52: 6310-6317 (1992), respectively).

20 III. The Effector Molecule.

As described above, the effector molecule component of the chimeric molecules of this invention may be any molecule whose activity it is desired to deliver to cells that overexpress IL-13 receptors. Particularly preferred effector molecules include cytotoxins such as PE or DT, radionuclides, ligands such as growth factors, antibodies,
25 detectable labels such as fluorescent or radioactive labels, and therapeutic compositions such as liposomes and various drugs.

A) Cytotoxins.

Particularly preferred cytotoxins include *Pseudomonas* exotoxins, Diphtheria toxins, ricin, abrin, cytotoxic prodrugs, ribonucleases (e.g., Ribonuclease
30

A), and ribozymes. *Pseudomonas* exotoxin and *Diphtheria* toxin, doxorubicin and maytansinoids are most preferred.

i) *Pseudomonas* exotoxin (PE).

Pseudomonas exotoxin A (PE) is an extremely active monomeric protein
5 (molecular weight 66 kD), secreted by *Pseudomonas aeruginosa*, which inhibits protein synthesis in eukaryotic cells through the inactivation of elongation factor 2 (EF-2) by catalyzing its ADP-ribosylation (catalyzing the transfer of the ADP ribosyl moiety of oxidized NAD onto EF-2).

The toxin contains three structural domains that act in concert to cause
10 cytotoxicity. Domain Ia (amino acids 1-252) mediates cell binding. Domain II (amino acids 253-364) is responsible for translocation into the cytosol and domain III (amino acids 400-613) mediates ADP ribosylation of elongation factor 2, which inactivates the protein and causes cell death. The function of domain Ib (amino acids 365-399) remains undefined, although a large part of it, amino acids 365-380, can be deleted without loss
15 of cytotoxicity. See Siegall *et al.*, *J. Biol. Chem.* 264: 14256-14261 (1989).

Where the targeting molecule (*e.g.* IL-13) is fused to PE, a preferred PE molecule is one in which domain Ia (amino acids 1 through 252) is deleted and amino acids 365 to 380 have been deleted from domain Ib. However all of domain Ib and a portion of domain II (amino acids 350 to 394) can be deleted, particularly if the deleted
20 sequences are replaced with a linking peptide such as GGGGS.

In addition, the PE molecules can be further modified using site-directed mutagenesis or other techniques known in the art, to alter the molecule for a particular desired application. Means to alter the PE molecule in a manner that does not substantially affect the functional advantages provided by the PE molecules described
25 here can also be used and such resulting molecules are intended to be covered herein.

For maximum cytotoxic properties of a preferred PE molecule, several modifications to the molecule are recommended. An appropriate carboxyl terminal sequence to the recombinant molecule is preferred to translocate the molecule into the cytosol of target cells. Amino acid sequences which have been found to be effective
30 include, REDLK (as in native PE), REDL, RDEL, or KDEL, repeats of those, or other sequences that function to maintain or recycle proteins into the endoplasmic reticulum.

referred to here as "endoplasmic retention sequences". See, for example, Chaudhary *et al.*, *Proc. Natl. Acad. Sci. USA* 87:308-312 and Seetharam *et al.*, *J. Biol. Chem.* 266: 17376-17381 (1991).

5 Deletions of amino acids 365-380 of domain Ib can be made without loss of activity. Further, a substitution of methionine at amino acid position 280 in place of glycine to allow the synthesis of the protein to begin and of serine at amino acid position 287 in place of cysteine to prevent formation of improper disulfide bonds is beneficial.

10 In a preferred embodiment, the targeting molecule is inserted in replacement for domain Ia. A similar insertion has been accomplished in what is known as the TGF α -PE40 molecule (also referred to as TP40) described in Heimbrook *et al.*, *Proc. Natl. Acad. Sci., USA*, 87: 4697-4701 (1990) and in U.S. Patent 5,458,878.

Preferred forms of PE contain amino acids 253-364 and 381-608, and are followed by the native sequences REDLK or the mutant sequences KDEL or RDEL. Lysines at positions 590 and 606 may or may not be mutated to glutamine.

15 In a particularly preferred embodiment, the IL-13 receptor targeted cytotoxins of this invention comprise the PE molecule designated PE38QQR. This PE molecule is a truncated form of PE composed of amino acids 253-364 and 381-608. The lysine residues at positions 509 and 606 are replaced by glutamine and at 613 are replaced by arginine (Debinski *et al. Bioconj. Chem.*, 5: 40 (1994)).

20 In another particularly preferred embodiment, the IL-13 receptor targeted cytotoxins of this invention comprise the PE molecule designated PE4E. PE4E is a "full length" PE with a mutated and inactive native binding domain where amino acids 57, 246, 247, and 249 are all replaced by glutamates (*see, e.g., Chaudhary et al., J. Biol. Chem.*, 265: 16306 (1995)).

25 The targeting molecule (*e.g.* IL-13 or anti-IL-13R antibody) may also be inserted at a point within domain III of the PE molecule. Most preferably the targeting molecule is fused between about amino acid positions 607 and 609 of the PE molecule. This means that the targeting molecule is inserted after about amino acid 607 of the molecule and an appropriate carboxyl end of PE is recreated by placing amino acids
30 about 604-613 of PE after the targeting molecule. Thus, the targeting molecule is inserted within the recombinant PE molecule after about amino acid 607 and is followed

by amino acids 604-613 of domain III. The targeting molecule may also be inserted into domain Ib to replace sequences not necessary for toxicity. Debinski, *et al. Mol. Cell. Biol.*, 11: 1751-1753 (1991).

5 In a preferred embodiment, the PE molecules will be fused to the targeting molecule by recombinant means. The genes encoding protein chains may be cloned in cDNA or in genomic form by any cloning procedure known to those skilled in the art (see, e.g., Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, (1989)). Methods of cloning genes encoding PE fused to various ligands are well known to those of skill in the art (see, e.g., Siegall *et al.*, 10 *FASEB J.*, 3: 2647-2652 (1989); and Chaudhary *et al. Proc. Natl. Acad. Sci. USA*, 84: 4538-4542 (1987)).

Those skilled in the art will realize that additional modifications, deletions, insertions and the like may be made to the chimeric molecules of the present invention or to the nucleic acid sequences encoding IL-13 receptor-directed chimeric 15 molecules. Especially, deletions or changes may be made in PE or in a linker connecting an antibody gene to PE, in order to increase cytotoxicity of the fusion protein toward target cells or to decrease nonspecific cytotoxicity toward cells without antigen for the antibody. All such constructions may be made by methods of genetic engineering well known to those skilled in the art (see, generally, Sambrook *et al.*, *supra*) and may 20 produce proteins that have differing properties of affinity, specificity, stability and toxicity that make them particularly suitable for various clinical or biological applications.

ii) Diphtheria toxin (DT).

Like PE, diphtheria toxin (DT) kills cells by ADP-ribosylating elongation 25 factor 2 thereby inhibiting protein synthesis. Diphtheria toxin, however, is divided into two chains, A and B, linked by a disulfide bridge. In contrast to PE, chain B of DT, which is on the carboxyl end, is responsible for receptor binding and chain A, which is present on the amino end, contains the enzymatic activity (Uchida *et al.*, *Science*, 175: 901-903 (1972); Uchida *et al. J. Biol. Chem.*, 248: 3838-3844 (1973)).

30 In a preferred embodiment, the targeting molecule-Diphtheria toxin fusion proteins of this invention have the native receptor-binding domain removed by truncation

of the Diphtheria toxin B chain. Particularly preferred is DT388, a DT in which the carboxyl terminal sequence beginning at residue 389 is removed. Chaudhary, *et al.*, *Bioch. Biophys. Res. Comm.*, 180: 545-551 (1991).

Like the PE chimeric cytotoxins, the DT molecules may be chemically conjugated to the IL-13 receptor targeting molecule, but, in a preferred embodiment, the targeting molecule will be fused to the Diphtheria toxin by recombinant means. The genes encoding protein chains may be cloned in cDNA or in genomic form by any cloning procedure known to those skilled in the art. Methods of cloning genes encoding DT fused to various ligands are also well known to those of skill in the art (*see, e.g.*, Williams *et al. J. Biol. Chem.* 265: 11885-11889 (1990)).

The term "Diphtheria toxin" (DT) as used herein refers to full length native DT or to a DT that has been modified. Modifications typically include removal of the targeting domain in the B chain and, more specifically, involve truncations of the carboxyl region of the B chain.

iii) Cytotoxic prodrugs.

In another embodiment, the cytotoxic moiety is a cytotoxic prodrug or a moiety (*e.g.*, an enzyme) capable of converting a "cytotoxic" prodrug from its inactive (non-cytotoxic) prodrug form to its cytotoxic (active) form. The chimeric molecule bearing the "conversion enzyme" or the prodrug itself is contacted with the target (tumor) cell in the presence of an IL-4 receptor blocker. In the presence of the IL-4 receptor blocker the chimeric molecule specifically binds to tumor cells overexpressing IL-13 receptors thereby localizing the prodrug or "conversion enzyme" at the tumor site. The prodrug or "conversion enzyme" is then contacted with its corresponding conversion enzyme or prodrug thereby converting the prodrug into its cytotoxic form at the tumor site thereby causing the inhibition of growth or killing of tumor cells.

Suitable prodrugs are well known to those of skill in the art and include, for example, etoposide-4'phosphate or 7-(2'aminoethyl phosphate)mitomycin which are activated in the presence of alkaline phosphatase (AP) to effect killing of tumor cells.

Other prodrugs include the prodrug N-(p-hydroxyphenoxyacetyl)adriamycin which is

used in conjunction with penicillin V amidase (PVA) or 5-fluorocytosine which is used in conjunction with cytosine deaminase (CD) (*see, e.g.*, U.S. Patent 4,957,278).

iv. Ricin and Abrin

Ricin and abrin are plant derived cytotoxins well known to those of skill in the art. Like *Pseudomonas* exotoxin and Diphtheria toxin, ricin and abrin can also be linked to a targeting moiety (*e.g.*, a molecule that specifically binds the IL-13 receptor) for specific delivery to cell bearing a particular target molecule. Means of joining ricin and abrin to a targeting molecule are well known to those of skill in the art (*see, e.g.*, Pastan *et al.* *Ann. Rev. Biochem.*, 61: 331-354 (1992), Thrush *et al.*, *Ann. Rev. Imm.* 14: 49-71 (1996) and references cited therein).

B) Detectable labels.

Detectable labels suitable for use as the effector molecule component of the chimeric molecules of this invention include any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Useful labels in the present invention include magnetic beads (*e.g.* Dynabeads™), fluorescent dyes (*e.g.*, fluorescein isothiocyanate, texas red, rhodamine, green fluorescent protein, and the like), radiolabels (*e.g.*, ³H, ¹²⁵I, ³⁵S, ¹⁴C, or ³²P), enzymes (*e.g.*, horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and colorimetric labels such as colloidal gold or colored glass or plastic (*e.g.* polystyrene, polypropylene, latex, *etc.*) beads.

Means of detecting such labels are well known to those of skill in the art. Thus, for example, radiolabels may be detected using photographic film or scintillation counters, fluorescent markers may be detected using a photodetector to detect emitted illumination. Enzymatic labels are typically detected by providing the enzyme with a substrate and detecting the reaction product produced by the action of the enzyme on the substrate, and colorimetric labels are detected by simply visualizing the colored label.

C) Ligands.

As explained above, the effector molecule may also be a ligand or an antibody. Particularly preferred ligand and antibodies are those that bind to surface

markers on immune cells. Chimeric molecules utilizing such antibodies as effector molecules act as bifunctional linkers establishing an association between the immune cells bearing binding partner for the ligand or antibody and the tumor cells overexpressing the IL-13 receptor. Suitable antibodies and growth factors are known to those of skill in the art and include, but are not limited to, IL-2, IL-4, IL-6, IL-7, tumor necrosis factor (TNF), anti-Tac, TGF α , and the like.

D) Other therapeutic moieties.

Other suitable effector molecules include pharmacological agents or encapsulation systems containing various pharmacological agents. Thus, the targeting molecule of the chimeric molecule may be attached directly to a drug that is to be delivered directly to the tumor. Such drugs are well known to those of skill in the art and include, but are not limited to, doxorubicin, vinblastine, genistein, an antisense molecule, and the like.

Alternatively, the effector molecule may be an encapsulation system, such as a liposome or micelle that contains a therapeutic composition such as a drug, a nucleic acid (*e.g.* an antisense nucleic acid), or another therapeutic moiety that is preferably shielded from direct exposure to the circulatory system. Means of preparing liposomes attached to antibodies are well known to those of skill in the art. See, for example, U.S. Patent No. 4,957,735, Connor *et al.*, *Pharm. Ther.*, 28: 341-365 (1985)

IV. Attachment of the Targeting Molecule to the Effector Molecule.

One of skill will appreciate that the targeting molecule and effector molecules may be joined together in any order. Thus, where the targeting molecule is a polypeptide, the effector molecule may be joined to either the amino or carboxy termini of the targeting molecule. The targeting molecule may also be joined to an internal region of the effector molecule, or conversely, the effector molecule may be joined to an internal location of the targeting molecule, as long as the attachment does not interfere with the respective activities of the molecules.

The targeting molecule and the effector molecule may be attached by any of a number of means well known to those of skill in the art. Typically the effector

molecule is conjugated, either directly or through a linker (spacer), to the targeting molecule. However, where both the effector molecule and the targeting molecule are polypeptides it is preferable to recombinantly express the chimeric molecule as a single-chain fusion protein.

5

A) Conjugation of the effector molecule to the targeting molecule.

In one embodiment, the targeting molecule (*e.g.*, IL-13, cpIL-13, or anti-IL-13R antibody) is chemically conjugated to the effector molecule (*e.g.*, a cytotoxin, a label, a ligand, or a drug or liposome). Means of chemically conjugating molecules are well known to those of skill.

10

The procedure for attaching an agent to an antibody or other polypeptide targeting molecule will vary according to the chemical structure of the agent.

Polypeptides typically contain variety of functional groups; *e.g.*, carboxylic acid (COOH) or free amine (-NH₂) groups, which are available for reaction with a suitable functional group on an effector molecule to bind the effector thereto.

15

Alternatively, the targeting molecule and/or effector molecule may be derivatized to expose or attach additional reactive functional groups. The derivatization may involve attachment of any of a number of linker molecules such as those available from Pierce Chemical Company, Rockford Illinois.

20

A "linker", as used herein, is a molecule that is used to join the targeting molecule to the effector molecule. The linker is capable of forming covalent bonds to both the targeting molecule and to the effector molecule. Suitable linkers are well known to those of skill in the art and include, but are not limited to, straight or branched-chain carbon linkers, heterocyclic carbon linkers, or peptide linkers. Where the targeting molecule and the effector molecule are polypeptides, the linkers may be joined to the constituent amino acids through their side groups (*e.g.*, through a disulfide linkage to cysteine). However, in a preferred embodiment, the linkers will be joined to the alpha carbon amino and carboxyl groups of the terminal amino acids.

25

A bifunctional linker having one functional group reactive with a group on a particular agent, and another group reactive with an antibody, may be used to form the desired immunoconjugate. Alternatively, derivatization may involve chemical

30

5 treatment of the targeting molecule, *e.g.*, glycol cleavage of the sugar moiety of a the glycoprotein antibody with periodate to generate free aldehyde groups. The free aldehyde groups on the antibody may be reacted with free amine or hydrazine groups on an agent to bind the agent thereto. (See U.S. Patent No. 4,671,958). Procedures for generation of free sulfhydryl groups on polypeptide, such as antibodies or antibody fragments, are also known (See U.S. Pat. No. 4,659,839).

Many procedure and linker molecules for attachment of various compounds including radionuclide metal chelates, toxins and drugs to proteins such as antibodies are known. See, for example, European Patent Application No. 188,256; 10 U.S. Patent Nos. 4,671,958, 4,659,839, 4,414,148, 4,699,784; 4,680,338; 4,569,789; and 4,589,071; and Borlinghaus *et al.* *Cancer Res.* 47: 4071-4075 (1987). In particular, production of various immunotoxins is well-known within the art and can be found, for example in "Monoclonal Antibody-Toxin Conjugates: Aiming the Magic Bullet," Thorpe *et al.*, *Monoclonal Antibodies in Clinical Medicine*, Academic Press, pp. 168- 15 190 (1982), Waldmann, *Science*, 252: 1657 (1991), U.S. Patent Nos. 4,545,985 and 4,894,443.

In some circumstances, it is desirable to free the effector molecule from the targeting molecule when the chimeric molecule has reached its target site. Therefore, chimeric conjugates comprising linkages which are cleavable in the vicinity of the target 20 site may be used when the effector is to be released at the target site. Cleaving of the linkage to release the agent from the antibody may be prompted by enzymatic activity or conditions to which the immunoconjugate is subjected either inside the target cell or in the vicinity of the target site. When the target site is a tumor, a linker which is cleavable under conditions present at the tumor site (*e.g.* when exposed to tumor- 25 associated enzymes or acidic pH) may be used.

A number of different cleavable linkers are known to those of skill in the art. See U.S. Pat. Nos. 4,618,492; 4,542,225, and 4,625,014. The mechanisms for release of an agent from these linker groups include, for example, irradiation of a photolabile bond and acid-catalyzed hydrolysis. U.S. Pat. No. 4,671,958, for example, 30 includes a description of immunoconjugates comprising linkers which are cleaved at the target site *in vivo* by the proteolytic enzymes of the patient's complement system. In

view of the large number of methods that have been reported for attaching a variety of radiodiagnostic compounds, radiotherapeutic compounds, drugs, toxins, and other agents to antibodies one skilled in the art will be able to determine a suitable method for attaching a given agent to an antibody or other polypeptide.

5

B) Production of fusion proteins.

Where the targeting molecule and/or the effector molecule is relatively short (*i.e.*, less than about 50 amino acids) they may be synthesized using standard chemical peptide synthesis techniques. Where both molecules are relatively short the chimeric molecule may be synthesized as a single contiguous polypeptide. Alternatively the targeting molecule and the effector molecule may be synthesized separately and then fused by condensation of the amino terminus of one molecule with the carboxyl terminus of the other molecule thereby forming a peptide bond. Alternatively, the targeting and effector molecules may each be condensed with one end of a peptide spacer molecule thereby forming a contiguous fusion protein.

15

Solid phase synthesis in which the C-terminal amino acid of the sequence is attached to an insoluble support followed by sequential addition of the remaining amino acids in the sequence is the preferred method for the chemical synthesis of the polypeptides of this invention. Techniques for solid phase synthesis are described by Barany and Merrifield, *Solid-Phase Peptide Synthesis*; pp. 3-284 in *The Peptides: Analysis, Synthesis, Biology. Vol. 2: Special Methods in Peptide Synthesis, Part A.*, Merrifield, *et al. J. Am. Chem. Soc.*, 85: 2149-2156 (1963), and Stewart *et al.*, *Solid Phase Peptide Synthesis, 2nd ed.* Pierce Chem. Co., Rockford, Ill. (1984).

20

In a preferred embodiment, the chimeric fusion proteins of the present invention are synthesized using recombinant DNA methodology. Generally this involves creating a DNA sequence that encodes the fusion protein, placing the DNA in an expression cassette under the control of a particular promoter, expressing the protein in a host, isolating the expressed protein and, if required, renaturing the protein.

25

DNA encoding the fusion proteins (*e.g.* IL-13-PE38QQR) of this invention may be prepared by any suitable method, including, for example, cloning and restriction of appropriate sequences or direct chemical synthesis by methods such as the

30

phosphotriester method of Narang *et al.* *Meth. Enzymol.* 68: 90-99 (1979); the phosphodiester method of Brown *et al.*, *Meth. Enzymol.* 68: 109-151 (1979); the diethylphosphoramidite method of Beaucage *et al.*, *Tetra. Lett.*, 22: 1859-1862 (1981); and the solid support method of U.S. Patent No. 4,458,066.

5 Chemical synthesis produces a single stranded oligonucleotide. This may be converted into double stranded DNA by hybridization with a complementary sequence, or by polymerization with a DNA polymerase using the single strand as a template. One of skill would recognize that while chemical synthesis of DNA is limited to sequences of about 100 bases, longer sequences may be obtained by the ligation of
10 shorter sequences.

 Alternatively, subsequences may be cloned and the appropriate subsequences cleaved using appropriate restriction enzymes. The fragments may then be ligated to produce the desired DNA sequence.

 In a preferred embodiment, DNA encoding fusion proteins of the present
15 invention may be cloned using DNA amplification methods such as polymerase chain reaction (PCR). Thus, in a preferred embodiment, the gene for IL-13 is PCR amplified, using a sense primer containing the restriction site for NdeI and an antisense primer containing the restriction site for HindIII. In a particularly preferred embodiment, the primers are selected to amplify the nucleic acid starting at position 19, as described by
20 McKenzie *et al.* (1993), *supra*. This produces a nucleic acid encoding the mature IL-13 sequence and having terminal restriction sites. A PE38QQR fragment may be cut out of the plasmid pWDMH4-38QQR or plasmid pSGC242FdN1 described by Debinski *et al.* *Int. J. Cancer*, 58: 744-748 (1994), and by Debinski *et al.*, *Clin. Cancer. Res.*, 1: 1015-1022 (1995), respectively. Ligation of the IL-13 and PE38QQR sequences and
25 insertion into a vector produces a vector encoding IL-13 joined to the amino terminus of PE38QQR (position 253 of PE). The two molecules are joined by a three amino acid junction consisting of glutamic acid, alanine, and phenylalanine introduced by the restriction site.

 While the two molecules are preferably essentially directly joined
30 together, one of skill will appreciate that the molecules may be separated by a peptide spacer consisting of one or more amino acids. Generally the spacer will have no specific

biological activity other than to join the proteins or to preserve some minimum distance or other spatial relationship between them. However, the constituent amino acids of the spacer may be selected to influence some property of the molecule such as the folding, net charge, or hydrophobicity.

5 The nucleic acid sequences encoding the fusion proteins may be expressed in a variety of host cells, including *E. coli*, other bacterial hosts, yeast, and various higher eukaryotic cells such as the COS, CHO and HeLa cells lines and myeloma cell lines. The recombinant protein gene will be operably linked to appropriate expression control sequences for each host. For *E. coli* this includes a promoter such as the T7,
10 trp, or lambda promoters, a ribosome binding site and preferably a transcription termination signal. For eukaryotic cells, the control sequences will include a promoter and preferably an enhancer derived from immunoglobulin genes, SV40, cytomegalovirus, etc., and a polyadenylation sequence, and may include splice donor and acceptor sequences.

15 The plasmids of the invention can be transferred into the chosen host cell by well-known methods such as calcium chloride transformation for *E. coli* and calcium phosphate treatment or electroporation for mammalian cells. Cells transformed by the plasmids can be selected by resistance to antibiotics conferred by genes contained on the plasmids, such as the amp, gpt, neo and hyg genes.

20 Once expressed, the recombinant fusion proteins can be purified according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like (*see*, generally, R. Scopes, *Protein Purification*, Springer-Verlag, N.Y. (1982), Deutscher, *Methods in Enzymology Vol. 182: Guide to Protein Purification*, Academic Press, Inc.
25 N.Y. (1990)). Substantially pure compositions of at least about 90 to 95% homogeneity are preferred, and 98 to 99% or more homogeneity are most preferred for pharmaceutical uses. Once purified, partially or to homogeneity as desired, the polypeptides may then be used therapeutically.

30 One of skill in the art would recognize that after chemical synthesis, biological expression, or purification, the IL-13 receptor targeted fusion protein may possess a conformation substantially different than the native conformations of the

constituent polypeptides. In this case, it may be necessary to denature and reduce the polypeptide and then to cause the polypeptide to re-fold into the preferred conformation. Methods of reducing and denaturing proteins and inducing re-folding are well known to those of skill in the art (See, Debinski *et al.* *J. Biol. Chem.*, 268: 14065-14070 (1993); Kreitman and Pastan, *Bioconjug. Chem.*, 4: 581-585 (1993); and Buchner, *et al.*, *Anal. Biochem.*, 205: 263-270 (1992)). Debinski *et al.*, for example, describe the denaturation and reduction of inclusion body proteins in guanidine-DTE. The protein is then refolded in a redox buffer containing oxidized glutathione and L-arginine.

One of skill would recognize that modifications can be made to the IL-13 receptor targeted fusion proteins without diminishing their biological activity. Some modifications may be made to facilitate the cloning, expression, or incorporation of the targeting molecule into a fusion protein. Such modifications are well known to those of skill in the art and include, for example, a methionine added at the amino terminus to provide an initiation site, or additional amino acids placed on either terminus to create conveniently located restriction sites or termination codons.

V. The IL-4 receptor blocker.

As indicated above, in a preferred embodiment, the chimeric molecules of this invention are preferably contacted with tumor cells in the presence of a blocker of an IL-4 receptor. The blocker can be any moiety that specifically binds to the IL-4 receptor and thereby reduces and/or prevents binding of targeting moieties that are directed against the IL-13 receptor. IL-4 receptor blockers include, but are not limited to ligands, antibodies, and small organic molecules that specifically bind to the IL-4 receptor. Thus, for example, IL-4 itself, when added or otherwise upregulated, can act as an IL-4 receptor blocker for this invention. However, because systemic upregulation of IL-4 receptor activity can have pathophysiological consequences, preferred blockers bind to the IL-4 receptor with reduced or no agonistic activity. In addition to blocking the IL-13 targeting molecule, they also act to antagonize (competitively inhibit) IL-4.

Means of identifying and/or designing IL-4 antagonists are well known to those of skill in the art. Human interleukin-4 (IL-4) activates its cognate receptor system by sequential binding to two different receptor subunits. The first, high-affinity binding

step (e.g., K_d 100 pM) involves the interaction between IL-4 receptor α subunit (Beckmann *et al.*, In: *Interleukins: Molecular Biology and Immunology*. Chem. Immunol., Kishimoto, T., ed. 51: 2213-2218 (1992); Galizzi *et al.*, *Int. Immunol.*, 2: 669-675 (1990), and Idzerda *et al. J. Exp. Med.*, 171: 861-873 (1990)) and IL-4 amino acid residues located on helices A and C ((Kruse *et al. EMBO J.*, 12: 5121-5129 (1993), and Ramanathan *et al. Biochem.*, 32: 3549-3556 (1993)) The subsequent second binding step involves a signaling site on helix D of IL-4 (Kruse *et al. EMBO J.*, 3237-3244 (1992)) and a further receptor subunit which is believed to be the γ chain of the IL-2 receptor system.

10 The two-step binding scheme leads to a simple rationale for the design of antagonistic IL-4 variants (IL-4 receptor blockers). Simply mutating (*i.e.* destroying or disrupting) the second binding site of IL-4 produces a ligand that will bind to, but not activate the IL-4 receptor (*see, e.g.*, Cunningham *et al. Science*, 254: 821-825 (1991), De Vos, *et al.*, *Science* 255: 306-312, Fuh *et al. Science*, 256: 1677-1680 (1992), Kruse
15 *et al. EMBO J.*, 3237-3244 (1992)).

 As indicated by the cited references, methods of mutating IL-4 to produce IL-4 antagonists are well known to those of skill in the art. It is well known that amino acid residues on α -helix D of IL-4 are involved in the second binding site that mediates signal transduction. Thus, mutations, insertions, or deletions, that alter or disrupt the D
20 helix will generate IL-4 antagonists. For example, it is known that the signaling site of human IL-4 comprises side chains of Arg121, Tyr124, and Ser125. These residues thus provide particularly suitable sites for mutation.

 Preferred mutations will involve substituting one amino acid for another having different properties. Thus, for example, a negatively charged (at pH 6) amino
25 acid can be substituted for a positively charged, neutral polar or non-polar (at pH 6) amino acid. Mutations known to reduce or eliminate agonistic IL-4 activity include, but are not limited to substitution of arginine 121 with aspartic acid ([R121D]IL-4), substitution of serine 125 with aspartic acid ([S125D]IL-4), substitution of tyrosine 124 with aspartic acid ([Y124D]IL-4) (*see, e.g.*, Tony *et al. Europ. J. Biochem.*, 225: 659-
30 665 (1994)). Of course, multiple mutations can also be made. These include, but are not limited to [R121D,Y124D]IL-4, [R121D, S125D]IL-4, [Y124D, S125D]IL-4,

[R121D, Y124D, S125D]IL-4, and the like. Other variants can include deletions of C or g C-terminal amino acids.

One of skill will appreciate that IL-4R blockers can also be created by deleting large sections of IL-4 leaving only sufficient residues to maintain minimal
5 required structure and to mediate binding to the IL-4 receptor. Such peptide "mimetics" are well known to those of skill in the art and can be routinely produced by rational design using knowledge of the structure of the IL-4 and IL-4R interaction and/or by screening and/or "directed evolution" using IL-4R and tumor expressed IL-13R as positive and negative targets respectively. Methods of using phage display and directed
10 evolution for producing polypeptides that high specific affinities for a particular target molecule are well known to those of skill in the art (*see, e.g.*, Noren, *NEB Transcript*, 8: 1-5 (1996), Li *et al. Nature Biotechnology*, 14: 986-991 (1996), Moore *et al. Nature Biotechnology*, 14: 458-467 (1996), and Vaughan *et al. Nature Biotechnology*, 14: 309-314 (1996), Wrighton *et al., Science*, 273: 458-463 (1996), and references cited therein). The above-described IL-4 variants (*e.g.*, [Y119D]IL-4) and other IL-4R
15 blockers can be routinely made as described above, and screened as described below in Section VI.

One of skill in the art will appreciate that other moieties besides ligands such as IL-4 and its variants can be used to block IL-4 receptors. For example, anti-IL-4
20 antibodies can also be used to block binding of IL-13R targeting moieties to the IL-4 receptor. Antibodies that specifically bind to and block the IL-4 receptor are well known to those of skill in the art and are described, for example, by Reusch *et al. Eur. J. Biochem.*, 222: 491-499 (1994). Representative anti-IL-4R antibodies include, but are not limited to s103, s456, s6g7, sg24, and o2g6 (*see, e.g.*, Zurawski *et al. J. Biol. Chem.*, 13: 13869-13878 (1995)). One of skill in the art will appreciate that the
25 antibodies may be human or humanized as described above.

Small organic molecules can also be used to block the IL-4 receptor. Such small organic molecules can be rationally designed based on the extensive knowledge in the field regarding the IL-4 receptor binding site (*see, e.g.*, Müller *et al. J. Mol. Biol.*, 237: 423-436 (1994), Tony *et al., Eur. J. Biochem.*, 225: 659-665 (1994) and references cited therein) and/or screened for using high throughput screening
30

methodologies applied to combinatorial libraries. Screening methods involve screening the putative IL-4R blocker against IL-4 receptors and against IL-13 receptors to identify those that block IL-4R and not IL-13R. Methods of generating combinatorial libraries and screening such libraries using high-throughput methods are well known to those of skill in the art (*see, e.g.,* Baum, *C&EN* (Feb. 7, 1994): 20-26 and references cited therein).

In another embodiment, the IL-4 receptor blockers of this invention can be provided as chemical conjugates or as fusions with other molecules to increase their effective molecular weight and hence their serum half-life. The attachment or fusion may be to virtually any large molecule compatible with components in the serum of the subject organism. Thus, for example, the IL-4 receptor blocker may be conjugated or fused to a lipid, a protein (*e.g.,* serum albumin), a polysaccharide, an antibody or ligand, and the like. Of course, the conjugated or fused IL-4 receptor blocker will be screened for binding affinity to an IL-4 receptor as described below and in the examples.

VI. Screening blockers for efficacy.

Blockers suitable for use in this invention are readily identified by routine screening. In a preferred embodiment, the screening will entail utilizing the blocker in conjunction with an IL-4R directed and an IL-13R directed cytotoxin. Normal cells (having IL-4 receptors and few or no IL-13 receptors) and tumor cells overexpressing the IL-13 receptor will be contacted with the cytotoxin in the presence and absence of the putative blocker. Blockers that reduce or eliminate cytotoxic activity of the IL-13R directed chimeric molecule on normal cells, but cause little or no reduction in cytotoxicity on tumor cells are suitable for use in the methods of this invention.

In a preferred embodiment, the cytotoxicity of the chimeric toxins is determined using a colorimetric MTS ([3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) / PMS (phenazine methasulfate) cell proliferation as described in the Examples herein.

VII. Identification of Target Cells.

It was a surprising discovery of the present invention that tumor cells, overexpress IL-13 receptors. In particular, carcinoma tumor cells (*e.g.*, renal carcinoma cells) overexpress IL-13 receptors at levels ranging from about 2100 sites/cell to greater than 150,000 sites per cell. Similarly, gliomas and Kaposi's sarcoma also overexpress IL-13 receptors (IL-13R). Moreover, every cancer type tested to date appears to overexpress IL-13 receptors. Thus it appears that IL-13 receptor overexpression is general characteristic of a solid tumor neoplastic cell.

Thus, the methods of this invention can be used to target an effector molecule to virtually any neoplastic cell. Neoplasias are well known to those of skill in the art and include, but are not limited to, cancers of the skin (*e.g.*, basal or squamous cell carcinoma, melanoma, Kaposi's sarcoma, *etc.*), cancers of the reproductive system (*e.g.*, testicular, ovarian, cervical), cancers of the gastrointestinal tract (*e.g.*, stomach, small intestine, large intestine, colorectal, *etc.*), cancers of the mouth and throat (*e.g.*, esophageal, larynx, oropharynx, nasopharynx, oral, *etc.*), cancers of the head and neck, bone cancers, breast cancers, liver cancers, prostate cancers (*e.g.*, prostate carcinoma), thyroid cancers, heart cancers, retinal cancers (*e.g.*, melanoma), kidney cancers, lung cancers (*e.g.*, mesothelioma), pancreatic cancers, brain cancers (*e.g.* gliomas, medulloblastomas, pituitary adenomas, *etc.*) and cancers of the lymph system (*e.g.* lymphoma).

In a particularly preferred embodiment, the methods of this invention are used to target effector molecules to kidney cancers, colorectal cancers (especially colorectal carcinomas), to skin cancers (especially Kaposi's sarcoma), and to brain cancers (especially gliomas, and medulloblastomas).

One of skill in the art will appreciate that identification and confirmation of IL-13 overexpression by other cells requires only routine screening using well-known methods. Typically this involves providing a labeled molecule that specifically binds to the IL-13 receptor. The cells in question are then contacted with this molecule and washed. Quantification of the amount of label remaining associated with the test cell provides a measure of the amount of IL-13 receptor (IL-13R) present on the surface of that cell.

In a preferred embodiment, IL-13 receptor may be quantified by measuring the binding of ^{125}I -labeled IL-13 (^{125}I -IL-13) to the cell in question. Details of such a binding assay are provided in Example 1.

5 VIII. Pharmaceutical Compositions.

The chimeric molecules and IL-4 receptor blockers of this invention are useful for parenteral, topical, oral, or local administration, such as by aerosol or transdermally, for prophylactic and/or therapeutic treatment. The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the
10 method of administration; for example oral administration include powder, tablets, pills, capsules and lozenges. It is recognized that the fusion proteins and IL-4R blockers and pharmaceutical compositions of this invention, when administered orally, must be protected from digestion. This is typically accomplished either by complexing the chimeric molecule and/or blocker with a composition to render it resistant to acidic and
15 enzymatic hydrolysis or by packaging the chimeric molecule and/or blocker in an appropriately resistant carrier such as a liposome. Means of protecting proteins from digestion are well known in the art.

In one particularly preferred embodiment, the chimeric molecule and/or the blocker can be provided in a time-release formulation such that the blocker is
20 released and protects normal cells prior to their coming in contact with the chimeric molecule. Methods of preparing time-release formulations are well known to those of skill in the art (*see, e.g.*, U.S. Patents 5,079,005, 5,055,300, 4,690,825, 4,608,248, 4,434,152 and references therein).

In another embodiment, the blocker can be provided by upregulation of
25 endogenous compounds (*e.g.*, IL-4) that bind to IL-4 receptors. Alternatively, the subject organism can be transfected with one or more vectors or other delivery vehicles that encode and express one or more IL-4 receptor antagonists such as those described above (*i.e.*, [Y124D]hIL4 or [R121D, Y124D]hIL4).

A large number of delivery methods are well known to those of skill in
30 the art. Such methods include, for example liposome-based gene delivery (Debs and Zhu (1993) WO 93/24640; Mannino and Gould-Fogerite (1988) *BioTechniques* 6(7):

682-691; Rose U.S. Pat No. 5,279,833; Brigham (1991) WO 91/06309; and Felgner *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84: 7413-7414), and replication-defective retroviral vectors harboring an expression cassette capable of expressing the IL-4R blocker as part of the retroviral genome (*see, e.g.,* Miller *et al.* (1990) *Mol. Cell. Biol.* 10:4239 (1990); Kolberg (1992) *J. NIH Res.* 4:43, and Cornetta *et al.* *Hum. Gene Ther.* 2:215 (1991)). Widely used retroviral vectors include those based upon murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), Simian Immuno deficiency virus (SIV), human immuno deficiency virus (HIV), and combinations thereof. *See, e.g.,* Buchscher *et al.* (1992) *J. Virol.* 66(5) 2731-2739; Johann *et al.* (1992) *J. Virol.* 66 (5):1635-1640 (1992); Sommerfelt *et al.*, (1990) *Virol.* 176:58-59; Wilson *et al.* (1989) *J. Virol.* 63:2374-2378; Miller *et al.*, *J. Virol.* 65:2220-2224 (1991); Wong-Staal *et al.*, PCT/US94/05700, and Rosenberg and Fauci (1993) in *Fundamental Immunology, Third Edition* Paul (ed) Raven Press, Ltd., New York and the references therein, and Yu *et al.*, *Gene Therapy* (1994) *supra*).

15 In addition to viral particles, a variety of protein coatings can be used to target nucleic acids to selected cell types. For example, transferrin-poly-cation conjugates enter cells which comprise transferrin receptors. *See, e.g.,* Zenke *et al* (1990) *Proc. Natl. Acad. Sci. USA* 87: 3655-3659; Curiel (1991) *Proc. Natl. Acad Sci USA* 88: 8850-8854 and Wagner *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 89:6099-20 6013.

electrostatically to poly-l-lysine or poly-l-lysine-transferrin which has been linked to defective adenovirus mutants can be delivered to cells with transfection efficiencies approaching 90% (Curiel *et al.* (1991) *Proc Natl Acad Sci USA* 88:8850-8854; Cotten *et al.* (1992) *Proc Natl Acad Sci USA* 89:6094-6098; Curiel *et al.* (1992) *Hum Gene Ther* 25 3:147-154; Wagner *et al.* (1992) *Proc Natl Acad Sci USA* 89:6099-6103; Michael *et al.* (1993) *J Biol Chem* 268:6866-6869; Curiel *et al.* (1992) *Am J Respir Cell Mol Biol* 6:247-252, and Harris *et al.* (1993) *Am J Respir Cell Mol Biol* 9:441-447). The adenovirus-poly-l-lysine-DNA conjugate binds to the normal adenovirus receptor and is subsequently internalized by receptor-mediated endocytosis. The adenovirus-poly-l-lysine-DNA conjugate binds to the normal adenovirus receptor and is subsequently internalized by receptor-mediated endocytosis. Similarly, other virus-poly-l-lysine-DNA

conjugates bind the normal viral receptor and are subsequently internalized by receptor-mediated endocytosis. Accordingly, a variety of viral particles can be used to target vector nucleic acids to cells.

5 In another embodiment, the blocker can be introduced into the subject organism as a naked expression cassette injected *e.g.*, naked DNA. The naked DNA, utilizing enzymes provided by the host expresses the encoded IL-4R blocker (*see, e.g.*, Wolff *et. al.*, Science 247: 1465-1468 (1990)).

10 The pharmaceutical compositions of this invention are particularly useful for parenteral administration, such as intravenous administration or administration into a body cavity or lumen of an organ. The compositions for administration will commonly comprise a solution of the chimeric molecule dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, *e.g.*, buffered saline and the like. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized by conventional, well known sterilization
15 techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of chimeric molecule and IL-4R blocker in these formulations can vary
20 widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs.

Thus, a typical pharmaceutical composition for intravenous administration would be about 0.1 to 10 mg per patient per day. Dosages from 0.1 up to about 100 mg
25 per patient per day may be used, particularly when the drug is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ. Blocker concentrations will range from about 10 to 1000 times higher than that of the chimeric molecules. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in
30 more detail in such publications as *Remington's Pharmaceutical Science*, 15th ed., Mack Publishing

The compositions containing the present fusion proteins and/or IL-4 receptor blockers or a cocktail thereof (*i.e.*, with other proteins) can be administered for therapeutic treatments. In therapeutic applications, compositions are administered to a patient suffering from a disease, in an amount sufficient to cure or at least partially arrest the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's health.

Single or multiple administrations of the compositions may be administered depending on the dosage and frequency as required and tolerated by the patient. In any event, the composition should provide a sufficient quantity of the proteins of this invention to effectively treat the patient.

Among various uses of the cytotoxic fusion proteins of the present invention are included a variety of disease conditions caused by specific human cells that may be eliminated by the toxic action of the protein. One preferred application is the treatment of cancer, such as by the use of an IL-13 receptor targeting molecule (*e.g.* IL-13 or anti-IL-13R antibody) attached to a cytotoxin. These chimeric molecules are preferably utilized in conjunction with an IL-4 receptor blocker as described above.

Where the chimeric molecule comprises an IL-13 receptor targeting molecule attached to a ligand, the ligand portions of the molecule are chosen according to the intended use. Proteins on the membranes of T cells that may serve as targets for the ligand includes CD2 (T11), CD3, CD4 and CD8. Proteins found predominantly on B cells that might serve as targets include CD10 (CALLA antigen), CD19 and CD20. CD45 is a possible target that occurs broadly on lymphoid cells. These and other possible target lymphocyte target molecules for the chimeric molecules bearing a ligand effector are described in *Leukocyte Typing III*, A.J. McMichael, ed., Oxford University Press (1987). Those skilled in the art will realize ligand effectors may be chosen that bind to receptors expressed on still other types of cells as described above, for example, membrane glycoproteins or ligand or hormone receptors such as epidermal growth factor receptor and the like.

It will be appreciated by one of skill in the art that there are some regions that are not heavily vascularized or that are protected by cells joined by tight junctions

and/or active transport mechanisms which reduce or prevent the entry of macromolecules present in the blood stream. Thus, for example, systemic administration of therapeutics to treat some gliomas, or other brain cancers, is constrained by the blood-brain barrier. The entry of macromolecules into the subarachnoid space is obviously limited due to its anatomical organization as well.

One of skill in the art will appreciate that in these instances, the therapeutic compositions of this invention can be administered directly to the tumor site. Thus, for example, brain tumors (*e.g.*, gliomas) can be treated by administering the therapeutic composition directly to the tumor site (*e.g.*, through a surgically implanted catheter). Where the fluid delivery through the catheter is pressurized, small molecules (*e.g.* the therapeutic molecules of this invention) will typically infiltrate as much as two to three centimeters beyond the tumor margin.

Alternatively, the therapeutic composition can be placed at the target site in a slow release formulation. Such formulations can include, for example, a biocompatible sponge or other inert or resorbable matrix material impregnated with the therapeutic composition, slow dissolving time release capsules or microcapsules, and the like.

Typically the catheter or time release formulation will be placed at the tumor site as part of a surgical procedure. Thus, for example, where major tumor mass is surgically removed, the perfusing catheter or time release formulation can be emplaced at the tumor site as an adjunct therapy. Of course, surgical removal of the tumor mass may be undesired, not required, or impossible, in which case, the delivery of the therapeutic compositions of this invention may comprise the primary therapeutic modality.

25

IX. Diagnostic Kits.

In another embodiment, this invention provides for kits for the treatment of tumors or for the detection of cells overexpressing IL-13 receptors. Kits will typically comprise a chimeric molecule of the present invention (*e.g.* IL-13-label, IL-13-cytotoxin, IL-13-ligand, *etc.*) and an IL-4 blocking molecule (*e.g.*, [Y124D]hIL4 or [R121D, Y124D]hIL4). In addition the kits will typically include instructional

30

materials disclosing means of use of the chimeric molecule (*e.g.* as a cytotoxin, for detection of tumor cells, to augment an immune response, *etc.*). The kits may also include additional components to facilitate the particular application for which the kit is designed. Thus, for example, where a kit contains a chimeric molecule in which the effector molecule is a detectable label, the kit may additionally contain means of detecting the label (*e.g.* enzyme substrates for enzymatic labels, filter sets to detect fluorescent labels, appropriate secondary labels such as a sheep anti- mouse-HRP, or the like). The kits may additionally include buffers and other reagents routinely used for the practice of a particular method. Such kits and appropriate contents are well known to those of skill in the art.

EXAMPLES

The following examples are offered to illustrate, but not to limit the claimed invention.

15

Example 1

Identification of Cells that Overexpress IL-13

Recombinant human IL-4 and IL-13 were labeled with ^{125}I (Amersham Research Products, Arlington Heights, Illinois, USA) by using the IODO-GEN reagent (Pierce, Rockford, Illinois, USA) according to the manufacturer's instructions. The specific activity of the radiolabeled cytokines was estimated to range from 20 - 100 $\mu\text{Ci}/\mu\text{g}$ protein. For binding experiments, typically, 1×10^6 renal cell carcinoma (RCC) tumor cells were incubated at 4°C for 2 hours with ^{125}I -IL-13 (100 pM) with or without increasing concentrations (up to 500 nM) of unlabeled IL-13. In some experiments, IL-13R expression was examined as previously described (Obiri *et al. J. Clin. Invest.*, 91: 88-93 (1993))). The data were analyzed with the LIGAND program (Munson *et al. Anal. Biochem.*, 107: 220-239 (1980)) to determine receptor number and binding affinity.

25

30

Four human renal cell carcinoma (RCC) cell lines (WS-RCC, HL-RCC, PM-RCC, and MA-RCC) bound ^{125}I -IL-13 specifically and the density of IL-13R varied from 2100 sites per cell in WS-RCC cells to 150,000 sites per cell in HL-RCC cells (Table 1). This represents an increase in IL-13 receptor expression ranging from 15 to

about 500 fold as compared to normal immune cells. In contrast, IL-4 receptors overexpressed on cancers have been reported at concentrations as high as 4000 sites per cell. Scatchard analyses (Scatchard, *Ann. N. Y. Acad. Sci.*, 51: 660-663 (1949)) revealed that only one affinity class of receptors was expressed on each cell line. The
5 binding affinities (Kd) ranged between 100 pM to 400 pM in three RCC cell lines while HL-RCC cells expressed lower affinity receptors (Kd ~3 nM).

Although IL-13 responsiveness has previously been reported in human monocytes, B cells and pre-myeloid (TF-1) cells (*see, e.g. de Waal Malefyt, et al. J. Immunol.*, 151: 6370-6381 (1993), de Waal Malefyt, *et al. J. Immunol.*, 144: 629-633
10 (1993)), little was known about IL-13R structure or its binding characteristics in these, or any other cells. The present data show that freshly isolated human monocytes, EBV-transformed B cell line and TF-1 cell line express very few IL-13 binding sites (100-300/cell) compared to human RCC cells (Table 1). On the other hand, no binding of ¹²⁵I-IL-13 was observed on H9 T cells, LAK cells and resting or PHA activated PBL.
15 This is compatible with the fact that IL-13 responsiveness has not been observed in T lymphocytes (Punnonen *et al.*, *Proc. Natl. Acad. Sci. USA*, 90: 3730-3734 (1993)).

Table 1. Expression of IL-13 receptor by human cells.

Cell Types	IL-13 Binding Sites/cell ^a Mean \pm SD	Kd(nM) Mean \pm SD
Renal Cell Carcinoma (RCC)		
1. WS-RCC	2,090 \pm 367 (5)	0.247 \pm 0.12 (3)
2. MA-RCC	5,013 \pm 1,347 (5)	0.128 \pm 0.05 (2)
3. PM-RCC	26,500 \pm 5,000 (2)	0.394 \pm 0.26 (2)
4. HL-RCC	150,000 \pm 15,000 (3)	3.1 \pm 0.7 (2)
B Lymphocytes		
1. DH (EBV-transformed B cell line)	303 \pm 90 (4)	- ^d
2. RAJI (Burkitt's lymphoma)	UD ^c	-
Monocytes/Premyeloid cells ^e		
1. Peripheral blood monocytes	124	-
2. U937 (premonocytic)	UD	-
3. TF1.J61 (premyeloid)	130 \pm 1 (2)	-
T Lymphocytes/LAK cells ^f		
1. PHA-activated PBL	<30	-
2. MOLT-4 (T-cell leukemia)	UD	-
3. LAK cells	UD	-

^aIL-13 binding sites/cell were determined as described in Example 1.

^b (n)=number of experiments used to calculate mean \pm standard deviation.

^c UC=undetectable

^d The Kd could not be reliably calculated because of low binding of ¹²⁵I-IL-13

^e The peripheral blood derived monocytes (> 90% purity) were isolated by ficoll-hypaque density gradient followed by elutriation from a leukopac obtained from normal donor.

^f LAK cells and activated T-lymphocytes were generated by the culture of donor PBLs (10⁶/ml) with IL-2 (500 Units/ml) for 3 days or PHA (10 μ g/ml) for 3-4 days respectively.

Example 2

IL-13 and IL-4 Bind to Different Receptors

Recently, it was proposed that the IL-2R γ_c receptor subunit is associated with IL-13R (see, *e.g.*, Russell *et al. Science* 262: 1880-1883 (1993); Kondo *et al. Science*, 262: 1874-1877 (1993); Noguchi *et al. Science*, 262: 1877-1880 (1993); Kondo *et al. Science* 263: 1453-1454 (1994); Giri *et al. EMBO J.* 13: 2822-2830 (1994))) and IL-13R may share a common component with IL-4R (Zurawski *et al. EMBO J.* 12: 2663-2670 (1993); Aversa *et al. J. Exp. Med.* 178: 2213-2218 (1993)). To directly address these possibilities, radio-ligand binding experiments were performed, as described in Example 1, on HL-RCC and WS-RCC cells using 125 I-IL-4 or 125 I-IL-13 in the presence or absence of excess of either cytokine.

Unlabeled IL-4 more efficiently inhibited 125 I-IL-4 from binding to RCC cells (84%, and 72% displacement of total binding in WS-RCC and HL-RCC, respectively) than IL-13 which also displaced 125 I-IL-4 binding to these cells (61% of total binding in WS-RCC and 51% in HL-RCC) under similar conditions. On the other hand, while 125 I-IL-13 binding was effectively displaced by IL-13 (about 85% of total in both cell types), it was only minimally displaced by IL-4 (12% of total displacement in WS-RCC, and 7% in HL-RCC). These results indicate that IL-4 and IL-13 both interact with each other's receptors, however, the interaction is not identical since IL-4 inhibition of 125 I-IL-13 binding was weak and IL-13 inhibition of 125 I-IL-4 binding was not complete. These results agree with previous observations in which IL-13 was found to compete with IL-4 binding on TF-1 cells (Zurawski *et al.*, *EMBO J.* 12: 2663-2670 (1993)). However, in that report the converse experiment was not done. Here, the data show that even though IL-13 competed for IL-4 binding, IL-4 did not compete for IL-13 binding.

The competition by IL-13 for IL-4 binding sites on lymphoid MLA 144 cells and RAJI cell lines was also investigated. These cells were incubated with radiolabeled IL-4 with or without excess unlabeled IL-4 or IL-13. Excess unlabeled IL-4 effectively displaced labeled 125 I-IL-4 bound to MLA 144 and RAJI cells, while excess IL-13 could not compete this binding. This observation is at variance to that seen with RCC cells in which IL-13 competed for IL-4 binding. The inability of IL-13 to compete

for ^{125}I -IL-4 binding to MLA 144 is consistent with the observation that IL-13 did not bind to peripheral blood T (or MLA 144) cells.

Example 3

5 Subunit Structure of IL-13 and IL-4 Receptors

The subunit structure of IL-13R on RCC cells was investigated by crosslinking studies. Cells (5×10^6) were labeled with ^{125}I -IL-13 or ^{125}I -IL-4 in the presence or absence of excess IL-13 or IL-4 for 2 h at 4°C . The bound ligand was cross-linked to its receptor with disuccinimidyl suberate (DSS) (Pierce, Rockford, Illinois, USA) at a final concentration of 2 mM for 30 min. Cells were lysed in a buffer containing 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 0.02 mM leupeptin, 10 5.0 μM trypsin inhibitor, 10 mM benzamidine HCl, 1 mM phenanthroline iodoacetamide, 50 mM amino caproic acid, 10 $\mu\text{g/ml}$ pepstatin, and 10 $\mu\text{g/ml}$ aprotinin. The cell lysates were cleared by boiling in buffer containing 2-mercaptoethanol and analyzed by electrophoresis through 8% SDS/polyacrylamide gel. The gel was subsequently dried and autoradiographed. In some experiments, the receptor/ligand complex was immunoprecipitated from the lysate overnight at 4°C by incubating with protein A sepharose beads that had been pre-incubated with P7 anti hIL-4R or anti- γ_c antibody and analyzed as above.

20 The labeled ^{125}I -IL-13 cross-linked to one major protein on all four RCC cell lines and the complex migrated as a single broad band ranging between 68 and 80 kDa. A single band was also observed on human pre-myeloid TF-1.J61 cells only after much longer exposure of the gel. After subtracting the molecular mass of IL-13 (12 kDa), the size of IL-13 binding protein was estimated at 56 to 68 kDa. The ^{125}I -IL-13 cross-linked band was not observed when the crosslinking was performed in the presence of 200-fold molar excess of IL-13. In addition to the major band, a faint band of approximately 45 kDa was also observed in HL-RCC and PM-RCC but not on MA-RCC cells. This band appeared to be specifically associated with IL-13R because unlabeled IL-13 competed for the binding of ^{125}I -IL-13. This band could represent an IL-13R associated protein or a proteolytic fragment of the larger band. In contrast to the displacement of ^{125}I -IL-13 binding by unlabeled IL-13, an excess of unlabeled IL-4 did

not prevent the appearance of IL-13R band in RCC cell lines. IL-13 on the other hand competed for ^{125}I -IL-4 binding to both major proteins on WS-RCC cells. It is of interest that ^{125}I -IL-13-cross-linked protein was slightly larger in size in TF-1.J61, WS-RCC, PM-RCC, and HL-RCC cell lines compared to that seen in MA-RCC. Post-translational
5 modifications, such as glycosylation or phosphorylation, may account for this difference.

Example 4

Construction of an IL-13-PE Fusion Protein

Construction of a Plasmid Encoding IL-13-PE38QQR

10 To construct the chimeric toxin a coding region of the human interleukin 13 (hIL-13) gene (plasmid JFE14-SR α) (Minty *et al.*, *Nature*, 362: 248 (1993), McKenzie *et al.* *Proc. Natl. Acad. Sci. USA*, 90: 3735 (1987)) was fused to a gene encoding PE38QQR, a mutated form of PE, thereby producing a construct (phuIL-13-Tx) encoding the chimeric molecule. Specifically, a DNA encoding human IL-13 was
15 PCR-amplified from plasmid JFE14-SR α . New sites were introduced for the restriction endonucleases NdeI and Hind III at the 5' and 3' ends of the hIL-13 gene, respectively by PCR using a sense primer that incorporated the NdeI site and an antisense primer that incorporated the HindIII site.

The NdeI/HindIII fragment containing encoding hIL-13 was subcloned
20 into a vector obtained by digestion of plasmid pWDMH4-38QQR (Debinski *et al.* *Int. J. Cancer* 58: 744-748 (1994)) or plasmid pSGC242FdNI (Debinski *et al.* *Clin. Cancer Res.*, 1: 1015-1022 (1995)) with NdeI and HindIII, to produce plasmid phuIL-13-Tx. The 5' end of the gene fusion was sequenced and showed the correct DNA of hIL-13.

Human interleukin 4 (hIL-4) was cloned into an expression vector in a
25 similar way to hIL-13 using plasmid pWDMH4 (Debinski *et al.* *J. Biol. Chem.* 268: 14065-14070 (1993)) as a template for PCR amplification. Recombinant proteins were expressed in *E. coli* BL21 (λ DE3) under control of the T7 late promoter (*Id.*). In addition to the T7 bacteriophage late promoter, the plasmids also carried a T7 transcription terminator at the end of the open reading frame of the protein, an f1 origin
30 of replication and gene for ampicillin resistance (Debinski *et al.* *J. Clin. Invest.* 90: 405-411 (1992)). The plasmids were amplified in *E. coli* (HB101 or DH5 α high efficiency

transformation) (BRL) and DNA was extracted using Qiagen kits (Chatsworth, California, USA).

Expression and purification of recombinant proteins.

5 *E. coli* BL21 (λ DE3) cells were transformed with plasmids of interest and cultured in 1.0 liter of Super broth. Expressed recombinant human IL-13 and human IL-13-PE38QQR were localized in inclusion bodies. The recombinant proteins were isolated from the inclusion bodies as described by Debinski *et al.*, *J. Biol. Chem.* 268: 14065-14070 (1993). After dialysis, the renatured protein of human IL-13-PE38QQR
10 was purified on Q-Sepharose Fast Flow and by size exclusion chromatography on Sephacryl S-200HR (Pharmacia, Piscataway, New Jersey, USA) The initial step of hIL-13 or hIL-4 purification was conducted on SP-Sepharose Fast Flow (Pharmacia).

Protein concentration was determined by the Bradford assay (Pierce "Plus", Rockford, Illinois, USA) using BSA as a standard.

15 Human IL-13 and IL-13-PE38QQR were expressed at high levels in bacteria as seen in SDS-PAGE analysis of the total cell extract. After initial purification on SP-Sepharose (hIL-13) or Q-Sepharose (hIL-13-PE38QQR) the renatured recombinant proteins were applied onto a Sephacryl S-200 HR Pharmacia column. Human IL-13 and hIL-13-PE38QQR appeared as single entities demonstrating the very
20 high purity of the final products. The chimeric toxin migrated within somewhat lower than expected for 50 kDa protein M_r range which may be related to the hydrophobicity of the molecule. The biologic activity of the rhIL-13 was exactly the same as commercially obtained hIL-13.

25

Example 5

The Activity of an IL-13-PE Fusion Protein on Human Carcinoma Cells

Cytotoxic activity of hIL-13-PE38QQR

The cytotoxic activity of chimeric toxins, such as hIL-13-PE38QQR, were tested by measuring inhibition of protein synthesis. Protein synthesis was assayed by
30 plating about 1×10^4 cells per in a 24-well tissue culture plate in 1 ml of medium. Various concentrations of the chimeric toxins were added 20-28 h following cell plating.

After 20 h incubation with chimeric toxins, [^3H]-leucine was added to cells for 4 h, and the cell-associated radioactivity was measured. For blocking studies, rhIL-2, 4 or 13 was added to cells for 30 min before the chimeric toxin addition. Data were obtained from the average of duplicates and the assays were repeated several times.

5 Several established cancer cell lines were tested to determine if hIL-13-PE38QQR is cytotoxic to them. In particular, cancers derived from colon, skin and stomach were examined. The cancer cells were sensitive to hIL-13-PE38QQR with ID_{50} s ranging from less than 1 ng/ml to 300 ng/ml (20 pM to 6.0 nM) (ID_{50} indicates the concentration of the chimeric toxin at which the protein synthesis fell by 50% when
10 compared to the sham-treated cells). A colon adenocarcinoma cell line, Colo201, was very responsive with an IC_{50} of 1 ng/ml. A431 epidermoid carcinoma cells were also very sensitive to the action of hIL-13-toxin; the ID_{50} for hIL-13-PE38QQR ranged from 6 to 10 ng/ml. A gastric carcinoma CRL1739 cell line responded moderately to the hIL-13-toxin with an ID_{50} of 50 ng/ml. Another colon carcinoma cell line, Colo205, had a
15 poorer response with an ID_{50} of 300 ng/ml.

The cytotoxic action of hIL-13-PE38QQR was specific as it was blocked by a 10-fold excess of hIL-13 on all cells. These data suggest that a spectrum of human cancer cells possess hIL-13 binding sites and such cells are sensitive to hIL-13-PE38QQR chimeric toxin.

20 Because the hIL-13R has been suggested to share the γ_c subunit of the IL-2R (Russell *et al.* *Science* 262: 1880-1883 (1993)), the specificity of hIL-13-PE38QQR action on A431 and CRL1739 cells, the two cell lines with different sensitivities to the chimeric toxin was further explored. The cells were treated with hIL-13-PE38QQR with or without rhIL-2 at a concentration of 1.0 $\mu\text{g/ml}$ or 10 $\mu\text{g/ml}$. The
25 rhIL-2 did not have any blocking action on hIL-13-PE38QQR on the two cell lines, even at 10,000 fold molar excess over the chimeric toxin. These results indicate that the cell killing by the hIL-13-toxin is independent of the presence of hIL-2.

IL-4, unlike IL-2, blocks the action of IL-13-PE38QQR

30 Native hIL-4 was added to cells which were then treated with hIL-13-PE38QQR. Unexpectedly, it was found that hIL-4 inhibited the cytotoxic activity of the

hIL-13-toxin. This phenomenon was seen on all the tested cell lines, including Colo201, A431 and CRL1739. To investigate the possibility that hIL-13 and hIL-4 may compete for the same binding site, the cells were also treated with the hIL-4-based recombinant toxin, hIL-4-PE38QQR (Debinski *et al. Int. J. Cancer* 8: 744-748 (1994)).

5 The cytotoxic action of hIL-4-PE38QQR had already been shown to be blocked by an excess of hIL-4 but not of hIL-2 (*Id.*). In the present experiment hIL-13 potently blocked the cytotoxic activity of hIL-4-PE38QQR. Also, the action of another hIL-4-based chimeric toxin, hIL-4-PE4E (Debinski *et al. J. Biol. Chem.* 268: 14065-14070 (1993)), was blocked by an excess of hIL-13 on Colo201 and A431 cells. Thus, the
10 cytotoxicity of hIL-13-PE38QQR is blocked by an excess of hIL-13 or hIL-4, and the cytotoxic action of hIL-4-PE38QQR is also blocked by the same two growth factors. However, IL-2 does not block the action of either chimeric toxin. These results strongly suggest that hIL-4 and hIL-13 have affinities for a common binding site.

This conclusion was supported by the observation of one cytokine
15 blocking the effect of a mixture of the two chimeric toxins. When A431 cells were incubated with both hIL-3- and hIL-4-PE38QQR chimeric toxins concomitantly the cytotoxic action was preserved and additive effect was observed as expected. An excess of hIL-13 efficiently blocked the action of a mixture of the two chimeric toxins. Moreover, neither hIL-13 nor hIL-4 blocked cell killing by another mixture composed of
20 hIL-13-PE38QQR and TGF α -PE40, a chimeric toxin which targets the EGFR (TGF α -based chimeric toxin, TGF α -PE40) (Debinski *et al. Mol. Cell. Biol.*, 11: 1751-1753 (1991)). The same was observed on Colo201 cells.

25 *Reciprocal blocking of chimeric toxins by IL-13 and IL-4 is due to competition for binding sites.*

The binding ability of human IL-13 was compared to human IL-4-PE38QQR in competitive binding assays. Recombinant hIL-4-PE38QQR was labeled with ¹²⁵I using the lactoperoxidase method as described by Debinski *et al.*, *J. Clin. Invest.* 90, 405-411 (1992). Binding assays were performed by a standard saturation and
30 displacement curves analysis. A431 epidermoid carcinoma cells were seeded at 10⁵ cells per well in a 24-well tissue culture plates at 24 h before the experiment. The plates were

placed on ice and cells were washed with ice-cold PBS without Ca^{++} , Mg^{++} in 0.2% BSA, as described (*Id.*). Increasing concentrations of hIL-13 or hIL-4-PE38QQR were added to cells and incubated 30 min prior to the addition of fixed amount of ^{125}I -hIL-4-PE38QQR (specific activity $6.2 \mu\text{Ci}/\mu\text{g}$ protein) for 2 to 3 hours. After incubation, the cells were washed twice and lysed with 0.1 N NaOH, and the radioactivity was counted in a γ -counter.

Human IL-4-PE38QQR competed for the binding of ^{125}I -hIL-4-PE38QQR to A431 cells with an apparent ID_{50} of 4×10^{-8} M. In addition, hIL-13 also competed for the ^{125}I -hIL-4-PE38QQR binding site with a comparable potency to that exhibited by the chimeric protein. More extensive binding studies have shown that hIL-13 also competes for hIL-4 binding sites on human renal carcinoma cell lines.

The possibility of an influence of hIL-13 or hIL-4 on the process of receptor-mediated endocytosis and post-binding PE cellular toxicity steps was excluded by adding to cells: (i) native PE (PE binds to the α_2 -macroglobulin receptor), (ii) $\text{TGF}\alpha$ -PE40, and (iii) a recombinant immunotoxin C242rF(ab')-PE38QQR (Debinski *et al. Clin. Cancer Res.*, 1: 1015-1022 (1995)). C242rF(ab')-PE38QQR binds a tumor-associated antigen that is a sialylated glycoprotein (Debinski *et al. J. Clin. Invest.* 90: 405-411 (1992)). The expected cytotoxic actions of these recombinant toxins were observed and neither hIL-13 nor hIL-4 blocked these actions on A431 and Colo205 cells.

hIL-4 and hIL-13 compete for a common binding site on carcinoma cells but evoke different biological effects

Even though hIL-13 and hIL-4 compete for a common binding site, they induce different cellular effects. Protein synthesis was inhibited in A431 epidermoid carcinoma cells in a dose-dependent manner by hIL-4 alone, or by a ADP-ribosylation deficient chimeric toxin containing hIL-4 (Debinski *et al., Int. J. Cancer* 58: 744-748 (1994)). This effect of hIL-4 or enzymatically deficient chimeric toxin can be best seen with a prolonged time of incubation (≥ 24 h) and requires concentrations of hIL-4 many fold higher than that of the active chimeric toxin in order to cause a substantial decrease in tritium incorporation. However, when A431 cells were treated with various concentrations of hIL-13, no inhibition (or stimulation) of protein synthesis was

observed, even at concentrations as high as 10 $\mu\text{g/ml}$ of hIL-13 for a 72 h incubation. The same lack of response to hIL-13 was found on renal cell carcinoma cells PM-RCC. Thus, while hIL-13 and hIL-4 may possess a common binding site, they appear to transduce differently in carcinoma cells expressing this common site, such as A431 and PM-RCC cells.

Example 6

IL-13 Inhibits Growth of Human Renal Cell Carcinoma Cells Independently of the P140 IL-4 Receptor Chain

Since human renal cell carcinoma cells (RCC) express a large number of intermediate to high affinity IL-13 receptors, the effect of IL-13 on *in vitro* growth of RCC cells was determined. The interaction between the IL-13 receptor and the IL-4 receptor was evaluated by examining the effect of anti-IL-4 and anti-IL-4R antibodies on IL-13 binding to RCC cells and the IL-13 modulation of RCC cell proliferation.

Inhibition of RCC cell growth by IL-13.

Renal cell carcinoma cells - WS-RCC and PM-RCC were derived as described previously (Obiri *et al.*, *J. Clin. Invest.*, *supra*) and maintained in culture medium (CM) consisting of DMEM with 4.5 g/L glucose supplemented with 10% fetal bovine serum (FBS), glutamine (2 mM), HEPES buffer (10 mM), penicillin (100 U/ml) and streptomycin (100 $\mu\text{g/ml}$).

For proliferation assays, RCC cells were harvested, washed and resuspended in CM in which the FBS content was reduced to 0.5%. Ten thousand cells were plated in each well of a 96-well microtiter tissue culture plate and cultured overnight at 37°C in a 5% CO₂ environment. IL-13 and/or IL-4 (0-1000 ng/ml) were added and incubation continued for an additional 72 h. Some cultures were concurrently treated with anti-IL-4 or anti-IL-4R antibody (1-10 $\mu\text{g/ml}$). [³H]-thymidine (1 $\mu\text{Ci/well}$) was added for the final 20 h of incubation. At the end of the incubation, cells were detached with trypsin or by a rapid freeze/thaw cycle and harvested onto a glass fiber filter-mat with a cell harvester (Skatron, Lier, Norway). [³H]-thymidine uptake was determined with a Betaplate scintillation counter (LKB, Gaithersburg, MD).

IL-13 inhibited cellular proliferation by up to 50% in a concentration dependent manner in WS-RCC and PM-RCC cell lines. The PM-RCC cell line was more sensitive to IL-13 since 0.1 - 1 ng/ml IL-13 caused a maximum inhibitory effect. The other cell line, WS-RCC required as much as 100 ng/ml of IL-13 for maximum effect. In addition, IL-13 at concentration of 10 ng/ml reduced proliferation of HL-RCC cells by 33%. Higher concentrations of IL-13 (up to 2000 ng/ml) did not have additional growth inhibitory effect. This growth inhibitory effect of IL-13 is similar to that observed with IL-4 on human RCC cells.

In order to examine the effect of IL-13 on the viability of RCC cells, the cells were cultured with IL-13 (0 - 100 ng/ml) at 5×10^4 /MI in 12-well tissue culture plates. After 72 h, the cells were harvested with trypsin/versene, washed and diluted in trypan blue for cell counts. Viability was determined by trypan blue exclusion. In control cultures, the viability (mean \pm SD of quadruplicate samples) was $95 \pm 10\%$ while the viability in cultures treated with 10 or 100 ng/ml IL-13 was 92.5 ± 9.6 and 93 ± 8.9 respectively. Thus, IL-13 did not have direct cytotoxic effect on RCC cells.

Since IL-13 competes for IL-4 binding and a mutated form of IL-4 inhibited IL-13 and IL-4 effects (Zurawski *et al.*, *EMBO J.*, 12: 2663 (1993)), the ability of anti-IL-4 or anti-IL-4R antibody to block both IL-4 and IL-13 growth inhibitory effects was determined. For this experiment, WS-RCC cells were treated with IL-13 or IL-4 alone, or in the presence of a neutralizing polyclonal antibody to hIL-4 or a monoclonal antibody to IL-4R (M57). This approach was chosen because a suitable anti-hIL-13 was not readily available.

[3 H]-thymidine uptake was significantly inhibited ($p < 0.05$) in IL-13-treated cultures (1913 ± 364 cpm in treated vs 3222 ± 458 cpm in control) and in IL-4 treated cultures (2262 ± 210 cpm in treated vs 3222 ± 458 cpm in control). While the IL-4-mediated inhibition of proliferation was abrogated by a polyclonal anti-IL-4 antibody, the inhibitory effect of IL-13 was not affected by the addition of anti-IL-4 antibody. Furthermore, the anti-proliferative effect of IL-4 was also abrogated by M57, a monoclonal antibody against IL-4R, but the antiproliferative effect of IL-13 was not affected by this antibody.

When WS-RCC cells were treated with a combination of IL-4 and IL-13, the resulting inhibition of cellular proliferation was not significantly different from that seen in cultures treated with either cytokine alone. Thus, although IL-4 and IL-13 exert a similar effect on RCC cell growth, their actions could not be potentiated by using the two cytokines together.

Inhibition of RCC colony formation by IL-13.

To confirm the observed IL-13 mediated inhibition of RCC tumor cell proliferation, a colony formation assay was used to evaluate the effect of IL-13 on RCC cell growth. Five hundred RCC cells were plated in triplicate 100 cm² tissue culture-treated petri dishes and treated with various concentrations of IL-13. For comparative purposes, RCC cells were also similarly treated with IL-4. After a 10-day culture period, the percentages of colonies formed in control and cytokine treated groups were compared.

IL-13 inhibited colony formation in PM and WS RCC cells in a concentration dependent manner. A maximum of 34% reduction in colony formation was observed in WS-RCC cells. In repeated experiments, the maximum inhibition observed in PM-RCC cells ranged from 13 - 32%. The kinetics of the inhibition of colony formation in WS-RCC cells was similar to that observed in PM-RCC cells. By comparison, IL-4 inhibited colony formation in both cell lines to the same extent as did IL-13. However, PM-RCC cells appeared to be slightly more sensitive to the IL-4 effect than WS-RCC cells.

Effect of anti-IL-4R antibody on IL-13 binding.

As explained above, on human RCC cells, IL-13 compete for the binding of ¹²⁵I-IL-4 but IL-4 does not compete for the binding of ¹²⁵I-IL-13. In order to understand the mechanism underlying the inhibition of IL-4 binding by IL-13 and to evaluate the fidelity of ligand binding by IL-13R, the effect of anti-IL-4R antibody on ¹²⁵I-IL-13 binding to PM-RCC cells, which express both IL-4R and IL-13R, was examined. As a control, the effect of this antibody on ¹²⁵I-IL-4 binding to PM-RCC cells was also tested.

Recombinant human IL-4 and IL-13 were labeled with ^{125}I (Amersham Corp.) by using the IODO-GEN reagent (Pierce Chem. Co.) according to the manufacturer's instructions. Specific activity ranged from 20 to 80 $\mu\text{Ci}/\mu\text{g}$ for ^{125}I -IL-4 and 80 to 120 $\mu\text{Ci}/\mu\text{g}$ for ^{125}I -IL-13. About 1×10^6 cells were incubated with radio labeled ligand (0.64 nM) in a buffered medium alone or in the presence of excess cytokine (128 nM); monoclonal (M57) or polyclonal (P2, P3, P7) rabbit antibodies raised against human IL-4R. The antibodies were used at a final dilution of 1:64. The incubation was done at 4°C for 2 h in a shaking water bath. Cell bound radio-ligand was separated from free by centrifugation through an oil gradient and bound radioactivity determined in a gamma counter.

Both ^{125}I -IL-13 and ^{125}I -IL-4 specifically bound to PM-RCC cells ($181,650 \pm 3,182$ cpm and $9,263 \pm 576$ cpm respectively). Unlabeled IL-13 competed well for ^{125}I -IL-13 binding, however, neither IL-4 nor any of three different polyclonal antibodies to IL-4R competed for the binding of ^{125}I -IL-13 on PM-RCC cells. Similarly, a monoclonal antibody to IL-4R (M57) did not block the binding of ^{125}I -IL-13 to PM-RCC cells. In contrast, IL-4, IL-13 and anti-IL-4R antibody (P7) all competed for ^{125}I -IL-4 binding on these cells.

This Example demonstrates that IL-13 inhibits the proliferation of human RCC cells in a concentration dependent manner. A maximum of 50% growth inhibition was observed and this growth inhibitory effect of IL-13 was supported by the results of a colony formation assay. It is noteworthy that the same concentration range of IL-13 inhibited colony formation in both RCC cell lines. Although a similar magnitude of growth inhibition has been reported for IL-4, this is the first report of a direct anti-tumor effect of IL-13 on RCC cells. Furthermore, inhibitory effects of IL-4 on colony formation in RCC cells have not been previously reported.

The antitumor effects of IL-13 were independent of IL-4 and did not involve IL-4R. This is evidenced by the fact that polyclonal or monoclonal antibodies to IL-4 or to the 140 kDa subunit of IL-4R had no effect on the growth inhibitory effect of IL-13. As was previously observed with IL-4, the inhibitory effect of IL-13 on RCC growth was cytostatic rather than cytotoxic since the viability in cells cultured with 10 or 100 ng/ml IL-13 was similar to that observed in control cultures after 72 h treatment.

Recently, IL-13 was shown to directly inhibit the proliferation of normal and leukemic B precursor cells in vitro by 30% (Renard *et al.*, *Blood*, 84: 2253-(1994)). This growth inhibitory effect of IL-13 was abrogated by an antibody to the 140 kDa subunit of IL-4R. Similarly, the growth stimulatory effect of IL-13 on TF-1 cells was also shown to be blocked by an antibody to IL-4R (*e.g.*, Tony *et al.*, *Europ. J. Biochem.*, 225: 659 (1994)). However, in this study, none of 3 different antibodies to IL-4R blocked the growth inhibitory effect of IL-13. These contrasting findings may suggest that the antibodies used in this study and those used by others are directed at different epitopes on the IL-4R protein. An alternative explanation, which we favor, is that IL-13R on RCC are structurally different from those expressed on lymphoid cells.

Structural differences between IL-4R expressed on RCC and those expressed on lymphoid cells have been identified. These include the absence of the common gamma chain of the receptors for IL-2, 4, 7, 9, and 15 in tumor cell IL-4R, although this chain is present in IL-4R of immune cells (Obiri *et al.* *Oncol. Res.*, 6: 419 (1994)).

Previous studies have demonstrated that antibodies to IL-4R block cellular responsiveness to IL-13 (Tony *et al.*, *Europ. J. Biochem.*, 225: 659 (1994)). However, the effect of these antibodies on the binding of ¹²⁵I-IL-13 to the cells was not investigated. We report here that the binding of radio-labeled IL-13 to its receptors on RCC cells could not be blocked by a polyclonal antibody to IL-4R which did block the binding of radio-labeled IL-4 to its receptors. These data suggest that in RCC cells, IL-13 interaction with its receptor does not involve the 140 kDa subunit of IL-4R and IL-13 effects are probably mediated by receptors that are not shared with IL-4.

Nevertheless, results from the above described Examples do suggest some common element(s) between IL-4R and IL-13R. For example, IL-13 binds to a ~70 kDa protein and competes for IL-4 binding but IL-4 does not compete for IL-13 binding in RCC cells. In addition, IL-4 cross links to a ~70 kDa protein in addition to its primary 140 kDa binding protein. Taken together, these data suggest that the ~70 kDa protein binds both IL-13 and IL-4. This indicates that the ~70 kDa protein may be a homodimer in which one of the constituents binds IL-13 alone while the other binds both IL-13 and IL-4. The data further suggest that because it binds to both putative

components of the ~70 kDa protein, IL-13 has a higher binding affinity to this protein than does IL-4 which appears to bind, at most, one component of the IL-13 receptor. Such an arrangement explains the finding that IL-13 competes for ^{125}I -IL-4 binding while IL-4 does not compete for ^{125}I -IL-13 binding on these cells. Finally, since antibody to IL-4R did not block IL-13 binding, and ^{125}I -IL-13 cross linking to the p140 form of the IL-4R was not detected, in RCC cells, IL-13 does not appear to utilize the 140 kDa IL-4 binding subunit.

The observation that the combination of IL-4 and IL-13 does not inhibit RCC cell proliferation any better than either cytokine alone suggests that the anti-proliferative effects of IL-4 and IL-13 are mediated through a common receptor subunit or common signaling pathway. This is consistent with the notion of a shared receptor or receptor component for the two cytokines and the observation that both IL-13 and IL-4 phosphorylate a member of the Janus family of kinases (JAK 1) as well as the 140 kDa subunit of IL-4R and activate the same signal transducer and activator of transcription (STAT 6) proteins in different cell types.

In summary, IL-13, like IL-4 directly inhibits RCC proliferation in vitro. The IL-13 effect is independent of IL-4 since anti-IL-4R antibody did not inhibit IL-13 binding to its receptor and anti-IL-4R antibody did not inhibit the IL-13 effect on RCC cells. These findings suggest that IL-13R directed chimeric molecules are particularly useful for the management of RCC.

Example 7

Targeting of Interleukin-13 Receptor on Human Renal Cell Carcinoma Cells by Recombinant IL-13-PE Cytotoxins

Cytotoxicity of IL-13-toxin fusion protein.

The cytotoxic activity of IL4-toxins was tested as described above. Typically, 10^4 RCC tumor cells or other cells were cultured in leucine-free medium with or without various concentrations of IL-toxin for 20-22 hours at 37°C. Then 1 μCi of [^3H]-Leucine (NEN Research Products, Wilmington, Delaware, USA) was added to each well and incubated for an additional 4 hours. Cells were harvested and radioactivity

incorporated into cells was measured by a Beta plate counter (Wallac-LKB, Gaithersburg, Maryland, USA).

Four primary cell cultures (PM-RCC, WS-RCC, MA-RCC & HL-RCC) and 1 long term culture (RC-2) of RCC cell lines were tested because of the large number of IL-13 receptors expressed by human RCC cells (*see* Example 1). RCC cells were sensitive to the cytotoxic activity of IL13-toxin with IC_{50} ranging from as low as 0.03 ng/ml to 350 ng/ml (<2 fM to 1 nM) (Table 2). All four primary cultures of RCC cells generated in our laboratory (18) seemed to be more sensitive to IL13-PE38QQR compared to long term RCC cell line (CAKI-1). The cytotoxic activity of IL13-toxin was specific and mediated through IL-13R, because excess IL-13 neutralized the cytotoxic activity of IL13-toxin. Thus, RCC cells are killed by IL13-PE38QQR at uniquely low concentrations of the chimeric protein (IL13-PE38QQR (474 amino acid protein) is composed of IL-13 (114 N-terminal amino acids) and domain II and domain III of PE molecule (Debinski *et al.*, *J. Biol. Chem.*, 270: 16775 (1995)).

Table 2. Cytotoxic activity of IL13-PE38QQR on human RCC tumor cell lines.

Tumors	IC_{50} (ng/ml) ^a mean \pm SD	IL-13 binding sites/cell	Reference No.
HL-RCC	0.03, < 0.1	150,000	13
PM-RCC	0.090 \pm 0.01	26,500	13
MA-RCC	0.340 \pm .15	5,000	13
WS-RCC	17.500 \pm 3.50	2,000	13
CAKI-1	350.000 ^b	< 100	- ^c

^a IC_{50} , the concentration of IL13-toxin at which 50% inhibition of protein synthesis is observed compared to untreated cells and was determined as described under "methods". The mean IC_{50} for individual tumors is shown and was determined from 2-5 experiments for four RCC tumor cell lines.

^bSingle experiment performed in quadruplicate using 5 different concentration of IL13-toxin.

^c current data

Correlation between IL-13R expression and sensitivity to IL13-toxin.

As described above, the primary RCC cell lines, such as PM-RCC, WS-RCC, HL-RCC, and MA-RCC expressed varied numbers of high- to intermediate-affinity IL-13R. However, IL-13 binding characteristics on CAKI-1 RCC cell line was not determined. IL-13 binding studies were therefore performed on these RCC cells utilizing [¹²⁵I]-IL-13.

IL-13 was iodinated with IODOGEN reagent (Pierce, Rockford, Illinois, USA) according to manufacturer's instructions. The specific activity of radio-labeled IL-13 ranged between 44 to 128 $\mu\text{Ci}/\mu\text{g}$. The IL-13 binding assay was performed by as described above (*see* Example 1). Briefly, RCC tumor cells were harvested after brief incubation with versene (Biowhittaker), washed three times in Hanks balanced salt solution and resuspended in binding buffer (RPMI 1640 plus 1 mM HEPES and 0.2% human serum albumin). For IL-13 displacement assay, RCC ($1 \times 10^6/100 \mu\text{l}$) cells were incubated at 4°C with ¹²⁵I-IL-13 (100-200 pM) with or without increasing concentrations of unlabeled IL-13 or IL13-PE38QQR. Following a 2 h incubation, cell bound radio-ligand was separated from unbound by centrifugation through a phthalate oil gradient and radioactivity determined with a gamma counter (Wallac).

CAKI-1 RCC cell line did not bind radiolabeled IL-13 well and only expressed < 100 IL-13 binding sites/cell (Table 1). The sensitivity of these cell lines to IL13-toxin also varied depending on the number of IL-13 binding sites per cell. CAKI-1 RCC cell line expressed the least number of IL-13 binding sites and were least sensitive to IL13-toxin. In contrast, HL-RCC cells were extremely sensitive and expressed 150,000 IL-13 binding sites/cell.

In vivo passage of MA-RCC does not decrease sensitivity to IL13-toxin.

In order to determine the antitumor activity of IL13-toxin against human RCC, human RCC cells were grown as subcutaneous tumors in nude mice. irradiated (300 rads) nude mice and in SCID mice. However, these RCC cells did not grow consistently in any of these immunoincompetent mice. In some cases tumors did grow very slowly but became centrally necrotic with a white rim of viable RCC cells.

Therefore, antitumor activity of IL13 toxin was not evaluated *in vivo*. However, MA-RCC were passaged in nude mice and the passaged tumors were used to prepare single cell suspensions. These cells did grow in tissue culture and after 1-3 passages, their sensitivity to IL13-toxin was determined.

5 MA-RCC were very sensitive to IL13-toxin and passaging of these RCC cells *in vivo* twice did not decrease their sensitivity. These data suggest that IL-13R levels do not change by *in vivo* passaging of RCC tumor cells.

10 *IL13-toxin is not cytotoxic to immune cells, monocytes, bone marrow-derived cells, and Burkitt's lymphoma cells.*

The cytotoxic activity of IL13-PE38QQR was also examined on PHA-activated T cells, a CD4+ T cell lymphoma line (H9), normal bone marrow cells, EBV-transformed B cell line, 2 Burkitt's lymphoma cell lines and a premonocytic cell line (U937). As shown above in Example 1, PHA-activated T cells, H9 cells, and U937
15 cells did not express detectable numbers of IL-13R. Consistent with these observations, IL13-PE38QQR was not cytotoxic to any of these cell types. EBV-transformed B cell line did express about 300 IL13-binding sites/cell, however, IL13-toxin was not cytotoxic to them. Although IL-13R expression was not tested on human bone marrow cells or Burkitt's lymphoma cell lines; based on their insensitivity to IL13-toxin, it is
20 expected that these cells also do not express IL-13R or express a low number of these receptors.

Clonogenic assay.

The antitumor activity of IL13-PE38QQR was also tested by a colony-
25 forming assay. Five hundred PM-RCC cells were plated in 100 mm petri dishes and the next day triplicate plates received IL-13 (20 ng/ml), IL13-PE38QQR (50 ng/ml) or control medium. The cells were cultured for 10 days at 37°C in a CO₂ incubator. Media was then removed and colonies were fixed and stained with 0.25% crystal violet in alcohol. Colonies containing 50 or more cells were scored. The surviving fraction was
30 calculated as the ratio of the number of colonies formed in treated and untreated cells and presented as percent survival.

Human PM-RCC cells formed colonies when 500 cells were cultured in petri dishes. Using this number of cells, PM-RCC cells formed 175 colonies with a clonogenic efficiency of 35%. When these cells were treated with IL13-PE38QQR for 10 days, only 32 colonies were formed (Table 3). However, 123 or 175 colonies were formed when cells were treated with recombinant IL-13 or media alone respectively.

Table 3. Effects of IL-13 and IL-13-PE38QQR on PM-RCC cells by clonogenic assay.

	No. Colonies \pm SD	% Surviving fraction
PM RCC:		
Control	175 \pm 5	100
IL13-PE38QQR	32 \pm 4	18
IL-13	123 \pm 3	70
HL RCC:		
Control	348 \pm 9	100
IL13-PE38QQR (5 ng/ml)	4 \pm 0.8	1
IL13-PE38QQR (15 ng/ml)	1 \pm 1	0.3
IL-13	232 \pm 12	67

IL-4 does not block the cytotoxic activity of IL13-PE38QQR on RCC cells.

IL-13 competed for the binding sites of IL-4 while IL-4 did not compete for the binding site of IL-13. However, in other cancer cell types IL-4 neutralized the cytotoxicity mediated by IL13-PE38QQR. The ability of IL-4 to neutralize the cytotoxicity of IL13-toxin on RCC cells was therefore tested. Only IL-13 blocked the cytotoxicity of IL13-toxin, while IL-4 did not block this cytotoxicity in all three RCC cell lines tested.

Binding affinity of IL13-toxin on human RCC cells.

The binding affinity of IL13-PE38QQR to IL-13R was then examined. HL-RCC or PM-RCC cells were utilized for this purpose. These cells were incubated

with a saturating concentration of radiolabeled IL-13 in the absence or presence of various concentrations of IL-13 or IL13-PE38QQR. In HL-RCC cells the IC_{50} (the protein concentration at which 50% displacement of [125 I]-IL-13 binding is observed) for native IL-13 was $\sim 20 \times 10^{-9}$ M, compared to $\sim 180 \times 10^{-9}$ M with IL13-PE38QQR. Thus
5 IL13-toxin bound to IL-13R with about 8-10 fold lower affinity compared to IL-13.

The foregoing experiments show that an IL-13 based cytotoxin, IL13-PE38QQR, is highly cytotoxic to human renal cell carcinoma cells. The IC_{50} in RCC cell lines ranged from less than 0.03 ng/ml to 350 ng/ml. The cytotoxicity of the IL13-toxin was specific and mediated through IL-13R because excess IL-13 neutralized the cell
10 killing activity of IL13-PE38QQR. These results corroborate with the data generated in a clonogenic assay that demonstrate a significant inhibition of colony formation by IL13-toxin.

Resting human cells including non-activated T cell line (H9), EBV-transformed B cell line, and promonocytic (U937) cell lines were not sensitive to the
15 cytotoxic effect of IL13-toxin. Similarly, PHA-activated human T cells and cells obtained from normal bone marrow biopsy were also insensitive to the cytotoxic effect of IL13-PE38QQR. It has previously been reported that hematologic progenitor cell lines and fresh human bone marrow cells express low numbers of IL-4 receptors (*e.g.*, Lowenthal *et al. J. Immunol.*, 140: 456 (1988)). However, IL-13R expression on these
20 cells has not been determined. A recent study reported that IL-13 has a direct regulatory role in the proliferation and differentiation of primitive murine hematopoietic progenitor cells (Jacobsen *et al. J. Exp. Med.*, 180: 75 (1994)) indicating expression of some level of IL-13R on these cells. However, the example shows that IL13-toxin was not cytotoxic to fresh bone marrow derived cells indicating that progenitor cells probably express
25 insufficient amount of IL-13R or receptors on these cells are not susceptible to the cytotoxic action of IL13-toxin.

It was shown above that IL-13 competes for the binding of IL-4 while IL-4 does not compete for the binding of IL-13 on RCC cells (Example 2). Similar to these results, the data in this example show that IL-4 does not neutralize the cytotoxic effect of
30 IL13-PE38QQR.

It has been previously demonstrated that IL4 based cytotoxin (IL4-PE4E) is highly cytotoxic to human RCC cells. A comparison was not made between IL13-PE38QQR and IL4-PE4E because the PE portion in these two chimeric proteins is different. However, both IL-13 and IL-4 competed with the cytotoxicity of IL4-toxin. Similarly, a mutant IL-4 protein blocked the proliferative response generated by IL-4 and IL-13. These data suggest that the receptors for IL-13 and IL-4 share a component.

The data on RCC cells showed that [¹²⁵I]-IL-13 crosslinked to one major protein of ~70kDa, which appeared to be similar in size to the smaller of the two subunits of IL-4R. The competition of IL-13 for the binding sites of IL-4, suggests that the ~70 kDa protein is shared between these two receptors. Also, IL-4 and IL-13 compete reciprocally to an internalized receptor form on some carcinoma cell lines. Recent data demonstrate that both IL-4 and IL-13 caused the phosphorylation of 140 kDa IL-4 binding protein. In addition, antibody to 140 kDa IL-4 binding protein blocked the effects of IL-13 on B cells. While these studies, suggest that the 140 kDa IL-4 binding protein may be shared between these two cytokine receptors, crosslinking of [¹²⁵I]-IL-13 to the 140 kDa protein was not observed even though [¹²⁵I]-IL-4 crosslinked to this protein. These data suggest that either the 140 kDa IL-4 binding protein does not share a chain with IL-13R or the 140 kDa protein is a non-IL-13 binding component of the IL-13R system which is why IL-4 does not compete for the binding of IL-13.

It is of interest to note that IL13-toxin binds to IL-13 receptor with a lower affinity compared to that of IL-13. Since PE molecule was attached to the C-terminus of the IL-13 molecule, these data suggest that, similar to IL-4, IL-13 may interact with its receptor predominantly through C-terminal end residues. In addition, these data also suggest that a chimeric IL13 toxin molecule in which the toxin moiety is attached at a site away from the C-terminus residues should be more cytotoxic to cancer cells.

In summary, these results indicate that IL13-toxin IL13-PE38QQR is highly cytotoxic to human RCC cells which express high numbers of IL-13R. Because resting or activated immune cells or bone marrow cells are not sensitive to IL13-toxin, the data indicate that this toxin is useful for the treatment of RCC without being cytotoxic to normal immune cells.

Example 8

Human Glioma Cells Overexpress IL-13 Receptors and Are Extremely Sensitive to IL-13PE Chimeric Proteins

In order to evaluate the efficacy of the chimeric immunotoxins of this invention on brain tumors, cytotoxicity (as evaluated by inhibition of protein synthesis) and competitive inhibition assays were performed on a number of brain tumor cell lines as described below.

Protein synthesis inhibition assay.

The cytotoxic activity of chimeric toxins (e.g., hIL13-PE38QQR) was tested on brain tumor cell lines. This group of cells is represented by human gliomas and includes U-373 MG, DBTRG-05 MG, A-172, Hs 683, U-251 MG, T-98G, SNB-19, and SW-1088, and also one human neuroblastoma SK-N-MC cell line. The majority of cell lines was obtained from the ATCC and they were maintained under conditions recommended by the ATCC. The SNB-19 cell line was obtained from National Cancer Institute/Frederick Cancer Research Facility, DCT tumor repository. Both SNB-19 and SW-1088 cell lines are of neuroglial origins.

Usually about 1×10^4 cells/well were plated in a 24-well tissue culture plate in 1 ml of medium and various concentrations of chimeric immunotoxin were diluted in 0.1 % bovine serum albumin (BSA)/phosphate-buffered saline (PBS) and 25 μ l of each dilution was added to 1 ml of cell culture medium. After 20 hr incubation with the immunotoxins, [3 H]-leucine was added to the cells for 3-5 hr, and the cell-associated radioactivity was measured using a beta counter.

For blocking studies (i) recombinant hIL13 (rhIL13) or (ii) rhIL4 was added to cells for 20-30 min before the addition of chimeric toxins (CTs). Data were obtained from the average of duplicates and the assays were repeated several times.

The cancer cells were sensitive to hIL13-PE38QQR with IC_{50} s ranging from less than 0.1 ng/ml to more than 300 ng/ml (2 pM to 6.0 nM). (The IC_{50} was calculated as the immunotoxin toxin concentration that causes 50% inhibition of tritiated leucine incorporation by the test cell line.) The cell lines fell into roughly three groups according to their responsiveness to the chimeric toxin. The first group consisting of U-

373 MG, U-251 MG, SNB-19, and A-172 was killed by hIL13-PE38QQR at the lowest concentrations with IC_{50} s ranging from less than 0.1 to 0.5 ng/ml (2 to 10pM). In particular, SNB-19 and A-172 had IC_{50} s of about 0.05 ng/ml. The second group of glioma cell lines composed of DBTRG MG and Hs-683 cells also responded very well to the hIL13-toxin with IC_{50} s in a range of 1-10 ng/ml (20-200 pM). The third group of glioma cell lines represented by T-98G and SW 1088 had poorer responses with IC_{50} s of 300 and > 1000 ng/ml, respectively. The only human cancer cell line of neural origin tested, the SK-N-MC neuroblastoma cell line, responded relatively poor to the chimeric toxin.

The cytotoxic action of hIL13-PE38QQR was specific as it was blocked by a 10- or 100-fold excess of hIL13 on the studied cells. These data indicate that most of the human glioma cancer cells examined possess hIL13 binding sites and such cells are extremely sensitive to hIL13-PE38QQR.

Cytotoxic activities of other cytokine-based chimeric proteins in glioma cells.

The cytotoxic action of hIL13-PE38QQR was compared to that of chimeric toxins containing other interleukins, such as hIL4 or hIL6. It has already been shown that some glioma cell lines can be killed by hIL4-PE4E with IC_{50} s exceeding 10 ng/ml (Puri *et al. Int. J. Cancer*, 58: 574-581 (1994)). hIL13-PE38QQR was cytotoxic to U-251 MG, U-373 MG and DBTRG MG cell lines with IC_{50} s much below 10 ng/ml. The cytotoxin hIL4-PE38QQR, a hIL4-based chimeric toxin resembling hIL13-PE38QQR, killed glioma cell lines, but at a concentration ranging from a factor of 10 to almost a factor of 1000 higher than that of hIL13-based toxin.

The IC_{50} s for hIL4-PE38QQR were higher than that seen with the hIL4-PE4E variant of the chimeric toxin (Debinski, *et al. J. Biol. Chem.*, 268: 14065-14070 (1993), Puri *et al. Int. J. Cancer*, 58: 574-581 (1994)) which is consistent with observations made with other growth factor-based chimeric proteins (Siegall *et al. Cancer Res.*, 51: 2831-2836 (1991)). Interestingly, hIL6-PE40 was also active on some human glioma cells and its activity was similar to that of the hIL4-toxin or better. However, hIL6-PE40 was still less active than the hIL13-based chimeric protein. These results show that human glioma cell lines are extremely sensitive to hIL13-PE38QQR

and the cytotoxic activity of the IL13 directed cytotoxin is considerably better than that of other interleukin-based chimeric toxins.

Competition of hIL4 for the cytotoxicity of hIL-13-PE38QQR.

5 The previous examples demonstrated that the action of hIL13-PE38QQR on several solid tumor cell lines is hIL13- and hIL4-specific, *i.e.*, it can be blocked by these two cytokines but not by IL2. However, it was also observed that hIL4 cannot compete for hIL13 binding sites (Obiri *et al. J. Biol. Chem.*, 270: 8797-8804 (1995)) and it cannot block the cytotoxic action of the hIL13-based chimeric protein on some
10 other cancer cell lines. Thus, the ability of hIL4 to block the IL13-toxin cytotoxin in glial cells was determined.

 The hIL4 cytokine was ineffective in preventing the cytotoxicity of hIL13-PE38QQR on both U-251 MG and U-373 MG cell lines. On the other hand, hIL13 did block the cytotoxic activity of hIL4-PE38QQR. Thus, the cytotoxicity of hIL13-
15 PE38QQR was blocked by an excess of hIL13 but not of hIL4, and the cytotoxic action of hIL4-PE38QQR was blocked by hIL13.

Human glioma cell lines express a number of receptors for IL13.

 To verify that the cytotoxic activity of hIL13-PE38QQR is specific and
20 mediated by hIL13 receptors, competitive binding assays were performed. Recombinant hIL13 was labeled with ¹²⁵I (Amersham Corp.) by using the IODO-GEN reagent (Pierce) according to the manufacturer's instructions, as previously described (Obiri *et al. J. Biol. Chem.*, 270: 8797-8804 (1995)). The specific activity of the radiolabeled
25 cytokines was estimated to range from 20 to 100 μ Ci/ μ g of protein. For binding experiments, typically 1×10^6 tumor cells were incubated at 4°C for 2 h with ¹²⁵I-hIL13 (100 pM) with or without increasing concentrations (up to 500 nM) of unlabeled cytokine. The data were analyzed with the LIGAND program (Munson, *et al., Anal. Biochem.* 107: 220-239 (1980)) to determine receptor number and binding affinity.

 Unlabeled hIL13 competed for the binding of ¹²⁵I-hIL13 to U-373 MG
30 cells efficiently. The Scatchard plot analyses of displacement experiments revealed one single binding site for hIL13 of intermediate affinity ($K_d = 1.8$ nM). There were around

16,000 binding sites for hIL13 on the U-373 MG cell line. The presence of hIL13 receptors in other human glioma cell lines was also evaluated. As seen in Table 4, the glioma cells had receptors for hIL13 ranging from 500 to 30,000 molecules per cell. The hIL-13Rs expressed in human glioma cells are of intermediate affinity with K_d s ranging from 1 to 2 nM. It is noteworthy that four out of five cell lines studied had very

Table 4. Human IL-13 binding to human glioma cells.

Cell Line	Binding Sites ^a molecules/cell (% CV)	K _d (nM)	hIL-13-PE38QQR IC ₅₀ (ng/ml)
A-172	22,600 (15)	1.6	< 1
U-251 MG	28,000 (12)	2.1	< 1
SNB-19	17,580 (19)	1.4	< 1
T-98G	549 (37)	1.0	200
U-373 MG	16,400 (14)	1.8	< 1

^a1 x 10⁶ cells were incubated with 125I-hIL-13 (100 pM) with or without increasing concentrations (up to 500 nM) of unlabeled hIL-13. Displacement curves and scatchard analyses were generated from the binding data using the LIGAND program (Munson *et al.*, *Analy. Biochem.*, 107: 220-239 (1980)).

high numbers of hIL-13R, *i.e.*, above 15,000 molecules per cell. The very same cell lines were also the most responsive to the action of hIL-13-PE38QQR (Table 1). The T-98 G cell line was poorly responsive to the hIL-13-toxin³ and was found to have only around 500 hIL-13 binding sites per cell (Table 1). Thus, specific hIL-13Rs are expressed in glioma cell lines and they mediate the cytotoxicity of hIL-13-PE38QQR.

These experiments establish that human glioma cell lines express large numbers of the receptor for the cytokine, IL13 and that it is possible to target hIL-13R with a chimeric toxin composed of the IL13 interleukin and a derivative of PE (*e.g.*, PE38QQR). The hIL13-PE38QQR toxin is extremely active on several glioma cell lines and most of these cell lines are killed at concentrations below 1 ng/ml (< 20 pM).

The action of hIL13-PE38QQR on glioma cells appears hIL13-specific because (i) hIL13 alone blocks the cytotoxicity of the chimeric toxin on all of the studied cell lines, and (ii) rhIL4 does not prevent the cytotoxic action of hIL13-PE38QQR on U-251 MG and U-373 MG glioma cells. The latter observation is different from the one made

on adenocarcinomas of the skin, stomach and colon origins (Debinski *et al.*, *J. Biol. Chem.*, 270: 16775-16780 (1995)). The action of IL13-PE38QQR was blocked efficiently by rhIL4 on these adenocarcinoma cell lines.

Receptors for IL4 and IL13 are complex and they have some common features detected in various systems, such as normal or malignant human cells. However, the U-251 MG cell line does not bind rhIL4 in a standard binding assay at 4°C while the number of hIL13 binding sites is high on these cells. This phenomenon most probably explains why rhIL4 does not block the action of hIL13-PE38QQR on these cells. Thus, the receptors for hIL13 and hIL4 in glioma cells are different from those found in several solid tumor cell lines.

The hIL13-PE38QQR cytotoxin is considerably more active on glioma cell lines than the comparable IL4-based chimeric toxin. This difference in cytotoxicity is presumably due to the difference in numbers of IL13 and IL4 molecules that can be bound by glioma cells. Many human glioma cells bind more than 15,000 and up to 30,000 molecules of IL13 per cell while these cells bind from less than 3,000 to very few molecules of IL4 per cell. Interestingly, some human glioma cells can also be killed by a chimeric toxin containing hIL6 (Siegall *et al.*, *Cancer Res.*, 51: 2831-2836 (1991)). However, the potency of hIL6-PE40 chimeric protein is lower from that of hIL13-PE38QQR.

Example 9

Chimeric Toxins Having Increased Cytotoxicity

Two chimeric toxins were produced that had higher specific toxicities than IL-13-PE38QQR. The first cytotoxin was an IL-13-PE4E toxin where PE4E is a "full length" PE with a mutated and inactive native binding domain where amino acids 57, 246, 247, and 249 are all replaced by glutamates.

The second fusion protein was circularly permuted human IL-13 (cpIL-13) fused to PE38QQR. In particular, the circularly permuted IL-13 was produced by selecting the methionine (Met) at position 44 of human IL-13 (hIL-13), just at the beginning of the putative second alpha-helix of hIL-13, as the "new" N-terminal end of the cytokine. The "old" N-, and C-termini were connected by a short peptide having the sequence Gly-GLy-Ser-Gly. The circularly permuted IL-13 (cphIL-13) was cloned in a

way that the "new" C-terminus of cphIL-13 (Gly-43 in a wild-type cytokine) was fused to the N-terminal Gly of PE38QQR.

The plasmid encoding cphIL-13-PE38QQR was constructed as follows: Plasmid phuIL13, encoding the 114 amino acids of hIL13 (*see, e.g., Debinski et al., J. Biol. Chem.* 270: 16775-16780 (1995)) served as a template for amplification of two separate fragments of hIL13; a fragment consisting of amino acids 1-43 and a fragment consisting of amino acids 44-114 or hIL-13 respectively. Both hIL13 1-43 and hIL13 44-114 were produced by PCR-amplification using two set of primers, primers cp1/cp2 and cp3/cp4, respectively (*see* Table 5, Sequence ID Nos. 1, 2, 3, and 4 respectively). Primers cp1 and cp4 introduced a new cloning site for Bam HI restriction endonuclease; primer cp2 encoded for a Hind III site and primer cp3 for Nde I restriction site. PCR-amplified cDNAs encoding for hIL13 1-43 (130 base-long) was cut with Bam HI and Hind III enzymes, and hIL13 44-114 (210 base-long) was cut with Nde I and Bam HI. These two fragments of DNA were ligated in a three-fragment ligation reaction to a vector encoding hIL13-PE38QQR (*Id.*) and cut with Nde I and Hind III restriction enzymes.

Table 5. PCR primers used to circularly permute hIL-13.

	PCR primer	Sequence	Sequence ID No.
20	cp1	5'-GTGACTGCAGGTGTCCATATGTACTGTGCAGCCCTGGA-3'	1
	cp2	5'-CCCAAACCGCGGGATCCACCGTTGAACCGTCCCTCGCGAA-3'	2
	cp3	5'-GCAGTCGTGGGTGGATCCGGCGGTTCCCCAGGCCCTGTGCCTCC-3'	3
	cp4	5'-TGGTGCAGCATCAAAGCTTTGCCAGCTGTCAGGTTGATGC-3'	4

The resulting plasmid, pCP/hIL13-PE38QQR, carried the cDNA for a circularly permuted hIL13 in which the new N-terminus starts at Met 44 of the wild type interleukin-13. Four additional amino acids (GlyGlySerGlyGly) are located in between the residues 114 and 1 of the wild type hIL13. Circularly permuted hIL13 was linked to the first amino acid of PE38QQR. The cphIL-13-PE38QQR was expressed in *E. coli* and purified to homogeneity.

Both hIL-13-PE4E and cphIL-13-PE38QQR exhibited cytotoxic activities that were two to ten fold better than those seen with hIL-13-PE38QQR. IC₅₀s were as

low as <0.1 ng/ml (<2 pM) on several glioma cell lines. Fresh human glioma explant cells were also killed at these low concentrations. The data suggest that the receptor for IL-13 is an excellent target for the treatment of human gliomas using IL-13R directed cytotoxins.

5

Example 10

Activity of IL-13R Directed Cytotoxins on Neural Cancers

The cytotoxicity of two chimeric toxins (hIL-13-PE38QQR and hIL-13PE4E) was tested on cancer cell lines of neural origins. The DAOY, TE671, and D283 medulloblastoma cell lines were all responsive to hIL-13 fused to PE4E. The IC_{50} s recorded in an MTS colorimetric cytotoxicity assay were in a range of <1 ng/ml to 50 ng/ml (<20 pM to 1 nM, respectively). In addition, human medulloblastoma explant cells also responded well to hIL-13-PE4E.

On the other hand, the SK-N-MC and Neuro-2A neuroblastoma cells were poorly responsive (IC_{50} s > 4 nM). The data, however, suggest that the overexpression of a receptor for hIL-13 is not restricted to gliomas, but it can be observed in neuron-derived cancers.

15

Example 11

IL-13R Targeted Cytotoxins are Effective Against Kaposi's Sarcoma

The recombinant immunotoxin IL-13-PE38QQR was also tested against Kaposi's sarcoma cell lines (NCB59, KS248, KS220B, KS54A, and ARL-13). All of the cell lines were cytotoxin sensitive with ID_{50} s ranging from about 8 ng/ml to about 180 ng/ml. The Kaposi's sarcoma cell lines all expressed IL-13 receptors at higher levels than normal cells, however the levels were lower than the IL-13R expression levels found in renal cell carcinoma or in gliomas.

25

Example 12

IL-4 Receptors are "Decoupled" from IL-13 Receptors on Tumor Cells

In this example the interactions between the human IL-13 receptor (hIL-13R) and the human IL-4 receptor (hIL-4R) are studied in human glioma cells. This

30

study utilizes established human glioma cell lines and, for the first time, cells of a human glioblastoma multiforme explant to test the cytotoxicities of chimeric toxins and responses to hIL-13 and hIL-4.

The results indicate that one predominant form of hIL-13R is overexpressed on tumor cells such as glioma cells. Unlike IL-13 receptors on "healthy" cells, these IL-13 receptors are not blocked by agents that bind to IL-4 receptors. The data indicate that blocking of IL-4 receptors will significantly increase the specificity of molecules directed to the IL-13 receptor.

10 Materials and Methods

Restriction endonucleases and DNA ligase were obtained from New England Biolabs (Beverly, Massachusetts, USA), Bethesda Research Laboratories (BRL, Gaithersburg, Maryland, USA) and Boehringer Mannheim (Indianapolis, IN). [³H]-leucine and ¹²⁵I were purchased from Amersham Corporation (Arlington Heights, Illinois, USA). Fast protein liquid chromatography (FPLC) columns, media, and Ficoll-Paque were purchased from Pharmacia (Piscataway, New Jersey, USA). Oligonucleotide primers were synthesized at Pharmacia's Gene Assembler at the Research Centre, HDM-UM. PCR kit was from Perkin-Elmer Cetus (Norwalk, Connecticut, USA). MTS/PMS (see below) for cell titer 96 aqueous non-radioactive cell proliferation assay was purchased from Promega (Madison, Wisconsin, USA).

Plasmids bacterial strains and cell lines

Plasmids carry a T7 bacteriophage late promoter, a T7 transcription terminator at the end of the open reading frame of the protein, a fl origin of replication and gene for ampicillin resistance (Debinski, *et al.*, *J. Clin. Invest.* 90:405-41 (1992)). The cDNA encoding sequence for hIL-13 was PCR-cloned to produce hILI13-PE38QQR, as described in Example 4 (*see also* Debinski, *et al.*, *J. Biol. Chem.* 270:16775-16780 (1995)). Recombinant proteins were expressed in *E. coli* BL21 (λDE3) under control of T7 late promoter (Studier, *et al.*, *J. Mol. Biol.* 189:113-130 (1986)). Plasmids were amplified in *E. coli* (HB101 or DH5α high efficiency

transformation) (BRL) and DNA was extracted using Qiagen kits (Chatsworth, California, USA).

5 The cytotoxic activity of chimeric toxins and antiproliferative activity of ILs were tested on several brain tumor cell lines, such as U-373 MG, DBTRG-05 MG, A-172, Hs 683, U-251 MG. and SW-1088. The majority of cell lines were obtained from the American Type Culture Collection(ATCC, Bethesda, Maryland, USA) and they were maintained under conditions recommended by the ATCC.

Glioma explant cells preparation.

10 Pathology proven surgical specimen of glioblastoma multiforme was collected and transferred to the laboratory under sterile conditions. Peripheral and necrotic tissue were excised and the remaining tissue minced using a scalpel. Tumor tissue was incubated in a cocktail composed of collagenase type 11 and IV, Dispase, and NuSerum/DMEM, at 37°C with constant shaking for 45 min. Cell suspension was then
15 passed through gauze and washed first with Hanks BSS and then with PBS (Ca⁺⁺, Mg⁺⁺-free). Cells were then layered on the Ficoll-Paque and centrifuged at 400 xg at 18-20°C for 35 min. The isolated cells were resuspended in 3x volume of balanced salt solution, centrifuged at 100 xg, at 18-20°C for 10 min. The pellet was washed one more time with the same solution and finally resuspended in RPMI 1640/25 mM HEPES
20 with L-glutamine and supplemented with 10% FCS, 0.1 ng/ml L-cystine, 0.02 mg/ml L-proline, 0.1 mg/ml sodium pyruvate, HT supplement and antibiotics. The cells were transferred into 100 mm plates and incubated at 37°C in 95% O₂/5% CO₂ humidified atmosphere.

25 *Expression and purification of recombinant proteins*

E coli BL21 (λDE3) cells were transformed with plasmids of interest and cultured in 1.0 liter of Super broth. The chimeric toxins and interleukins were localized to the inclusion bodies. The procedure for the recombinant proteins isolation from the inclusion bodies was described previously (Debinski, *et al.*, *J. Biol. Chem.*
30 268:14065-14070 (1993)). After dialysis, the renatured proteins were purified on

ion-exchange columns and by size exclusion chromatography on Sephacryl S-200HR (Pharmacia).

Protein concentration was determined by the Bradford assay (Pierce "Plus", Rockford, IL) using BSA as a standard.

5

Protein synthesis inhibition assay

The cytotoxic activities of chimeric toxins, such as hIL-13-PE38QQR and hIL-4-PE38QQR, were tested as follows: usually 5×10^3 cells per well were plated in a 96-well tissue culture plate in 200 μ l of media. Various concentrations of the chimeric toxins were diluted in 0.1 % BSA/PBS and 25 μ l of each dilution was added to cells 20-28 h following cell plating. Cells were incubated at 37°C for another 48 h. Then, the cytotoxicity was determined using a colorimetric MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt]/PMS (phenazine methasulfate) cell proliferation assay. MTS/PMS was added at a half final concentration as recommended by the manufacturer. The cells were incubated with the dye for 6 hr and then the absorbance was measured at 490 nm for each well using a microplate reader (Cambridge Technology, Inc., Watertown, Massachusetts, USA). The wells containing no cells or wells with cells treated with high concentrations of PE or hIL-13-PE38QQR (10 μ g/ml), or wells with no viable cells left served as a background for the assay. For blocking studies, rhIL-4 or rhIL-13 was added to cells for 60 min before the chimeric toxins addition. Data were obtained from the average of quadruplicates and the assays were repeated several times.

To evaluate the effects of interleukins on cell proliferation, the assays were performed as follows: 1×10^3 cells per well were plated in a 96-well tissue culture plate in 200 μ l of 0.5 % FBS-containing media and the interleukins were added 20 h following cell plating. After seven-day or five-day incubation with the interleukins, MTS/PMS was added to the cells for 6 h, and the assay was performed as described above for the chimeric toxins.

30

Competitive binding assay

Recombinant human IL-13 (rHIL-13) and recombinant IL-4 (rIL-4) labeled with ^{125}I (Amersham Corp.) using the IODO-GEN reagent (Pierce) according to the manufacturer's instructions. The specific activities of radiolabeled cytokines were estimated to be between 20 to 100 $\mu\text{Ci}/\mu\text{g}$ of protein of protein for ^{125}I -hIL-13 and 179 $\mu\text{Ci}/\mu\text{g}$ of protein for ^{125}I -hIL-4.

Binding experiments were performed as described in Example 1 and by Obiri, *et al.*, *J. Biol. Chem.* 270:8797-8804 (1995). Typically, 1×10^6 to 1.5×10^6 tumor cells were incubated at 4°C for 2 h with ^{125}I -hIL-13 (100-500 pM) or ^{125}I -hIL-4 (100-500pM with or without increasing concentrations (up to 1000 nM) of unlabeled interleukins. The data were analyzed with the LIGAND program (Obiri, *et al.*, *J. Biol. Chem.* 270:8797-8804 (1995); Munson, *et al.*, *Analy. Biochem.* 107:220-239 (1980)) to determine receptor number and binding affinity.

Results

hIL-13-PE38QQR is extremely cytotoxic to both established glioma cell lines and glioblastoma multiforme explant cells

The A-172, DBTRG MG, and Hs-683 established human glioma cell lines and, for the first time, glioma explant cells (G2) were tested to determine and/or confirm if hIL-13-PE38QQR is cytotoxic to them. All the established glioma cell lines were very responsive with an IC_{50} Of 0.1 to 5 ng/ml (Fig. 1). Of interest, human glioma explant cells were also extremely sensitive to the action of hIL-13-toxin; the IC_{50} for hIL-13-PE38QQR was 0.2 ng/ml (Fig. 1). The cytotoxic action of hIL-13-PE38QQR was specific as it was blocked by an excess of hIL-13 on all cells (*see, e.g.*, Example 5). These data demonstrate that both established glioma cell lines and a primary culture of glioma cells possess hIL-13 binding sites and such cells are extremely sensitive to hIL-13-PE38QQR chimeric toxin.

hIL-4 does not block the cytotoxicity of hIL-13-PE38QQR on glioma cell lines and glioma explant cells.

Because hIL-13R has been shown to be related to IL-4R (*see, e.g.,* Examples 4 and 5, Debinski, *et al., J. Biol. Chem.* 270:16775-16780 (1995); Obiri, *et al., J. Biol. Chem.* 270:8797-8804 (1995); Zurawski, *et al., EMBO J.* 12:2663-2670 (1993)), the specificity of hIL-13-PE38QQR action on the glioma cell lines and G2 explant cells was further explored. The cells were treated with hIL-13-PE38QQR with or without recombinant (r) hIL-4 at a concentration of 1.0 μ g/ml. The rhIL-4 did not have any blocking action against hIL-13-PE38QQR on either the established cultured cells (A-172, Hs 683, and DBTRG MG) or freshly explanted cultured glioma cells, even at a 1000-fold molar excess over the chimeric toxin (Fig. 1). These results indicate that the cell killing by the hIL-13-toxin on these cells is independent of the presence of hIL-4. The same results were obtained with the U-251 MG, U-373 MG (Example 8) and on U-87 MG and SNB-19 cell lines.

Since these data are in contrast to observation made on several adenocarcinoma cells (Example 5, Debinski, *et al., J. Biol. Chem.* 270:16775-16780 (1995)), the cytotoxicity experiments were repeated, for example, on Colo 201 human colon adenocarcinoma cells employing a colorimetric assay used in the present study (instead of tritium incorporation) and reproduced exactly same results.

hIL-13 blocks the action of hIL-4-toxins on the U-251 MG, DBTRG MG, and A-172 glioma cells, and glioma G2 explant cells.

To investigate the possibility that hIL-13 and IL-4 may nevertheless compete, although not reciprocally, for the same binding site on glioma cells, the cells were also treated with hIL-4-based recombinant toxin, hIL-4-PE38QQR (Debinski, *et al., Int. J. Cancer* 58:744-748 (1994)) (Fig. 2). It has previously been demonstrated that all tested glioma cell lines express specific 140 kDa hIL-4R, as determined by a immunoreactivity of an antibody raised against the protein (Puri, *et al., Int. J. Cancer* 58:574-581 (1994)). The data again show, unexpectedly, that hIL-4-PE38QQR was without any significant specific cytotoxicity to most of these cells (Fig. 2) including the Hs-683 and U-373 MG cells. Only the U-251 MG glioma cell line responded relatively

well to hIL-4-38QQR with an IC_{50} of 10 ng/ml. This cytotoxicity was blocked efficiently by an excess of hIL-13 (Fig. 2). Thus, the cytotoxicity of hIL-4-PE38QQR is blocked by an excess of hIL-13; however, the cytotoxic action of hIL-4-PE38QQR is absent on the majority of glioma cell lines and human glioma explant cells.

5 Since interleukins coupled to PE4E form of the toxin exhibit better cytotoxic activities on cancer cells (*e.g.*, Debinki *et al.*, *J. Biol. Chem.*, 268: 14065-14070), the glioma cells were also treated with hIL-4-PE4E. The higher cytotoxic potency of this chimeric protein when compared to hIL-4-PE38QQR was observed on several glioma cells as well as on G2 explant cells (Fig. 3). The IC_{50} ranged from 10 to
10 200 ng/ml on U-251 MG, DBTRG MG, A-172, G2 explant (Fig. 3), and U-87 MG cells. The cytotoxic action of hIL-4-PE4E was blocked by an excess of hIL-13 (Fig. 3) in a manner similar to the blocking of this cytotoxicity by hIL-4. The blocking on G2 cells was less than on other cell lines (Fig. 3) and a similar response was seen on SNB-19 cells.

15 These results demonstrate that hIL-4 and hIL-13 have a common binding site on the glioma cell lines and are reminiscent of the previous findings on a series of adenocarcinoma cells. However, there is also a profound difference between these and and previous findings, since the commonality is not reciprocal, *i.e.*, only hIL-13 is a competitor for the two receptors.

20

Antiproliferative effects of hIL-13 and hIL-4 on glioma cells.

 Despite being competitors for the same binding site on some cancer cells, differences in hIL-13- and hIL-4-induced cellular effects were observed (Example 5). Namely, protein synthesis was inhibited in A431 epidermoid carcinoma cells in a
25 dose-dependent manner by hIL-4, while hIL-13 had no effect on these cells, even at concentrations as high as 10 μ g/ml of hIL-13 for a 72 h incubation (Example 5). Similarly, hIL-13 had no effect on the growth of glioma cells. The U-251 MG, U-373 MG glioma cells (Fig. 4), and G2 explant cells (Fig. 4), were unaffected by the five-day and/or one-week treatment with IL-13. Human IL-4 also had no activity on the growth
30 of these cells (Fig. 4).

hIL-13 binding affinity to A-172 and G2 explant cells.

Competitive binding assays were performed to determine whether the hIL-13Rs on the established glioma cell lines, such as A-172 glioma cells, have different or similar binding affinity for hIL-13 compared to the hIL-13R that is expressed on freshly isolated cells. As shown in Figures 5A and 5B, unlabeled hIL-13 competed for the binding of ^{125}I -hIL-13 to A-172 cells efficiently (Fig. 5A). The Scatchard plot analysis of displacement experiments (Fig. 5B) revealed one single binding site for hIL-13 of intermediate affinity; $K_d = 1.6 \text{ nM}$. There are 22,600 binding sites for hIL-13 on the A-172 cell line. The competition of unlabeled hIL-13 for the binding of iodinated ligand (Fig. 6A) and the Scatchard analysis performed on G2 explant cells (Fig. 6B) have shown similar results to that obtained on A-172 cells. However, the number of binding sites on explant cells is 300,000 per cell with K_d of 2.4 nM. In another experiment, the estimate of hIL-13 binding sites indicated more than 500,000 binding sites per cell.

Thus, there is no difference in affinity of hIL-13 to its receptor whether or not cells are permanently cultured or are derived from the primary culture, although the explant cells seem to be considerably more enriched in hIL-13 receptors than the established glioma cell cultures.

hIL-4 does not compete for labeled hIL-13 binding sites, but hIL-13 is a competitor for ^{125}I -hIL-4 binding sites on glioma cells.

The first step in the action of a chimeric toxin is binding of the toxin to a specific (often internalized) receptor. Binding activity was investigated using standard competition experiments were performed at 4°C using radiolabeled ligands. As seen in Fig. 7A hIL-13 displaced labeled hIL-13 very efficiently on A-172 glioma cells. However, hIL-4 did not compete for the binding of ^{125}I -hIL-13 at all at up to 100 nM of the competitor. On the other hand, as shown above (Figs. 2 and 3), hIL-13 blocked the actions of both hIL-4-PE38QQR and hIL-4-PE4E on glioma cells. Therefore, the reverse assay was performed and it was determined that either interleukin was a competitor for ^{125}I -hIL-4 binding sites (Fig. 7B).

Thus, the results of binding experiments indicate that the non-reciprocal interference of interleukins with the cytotoxic activities of their respective chimeric

toxins on glioma cells is due to the non-reciprocal interference with the binding to the interleukin receptors.

hIL-13 is not a competitor for ¹²⁵I-hIL-4 binding sites on cells transfected with the 140 kDa hIL-4 receptor.

The foregoing experiments show that hIL13 blocks the cytotoxicities of hIL-4-based chimeric toxins and competes for the binding sites of ¹²⁵I-hIL-4 on glioma cells. The 140 kDa hIL-4R chain is believed to be a principal hIL-4 binding protein. Therefore, cells transfected with the hIL-4 receptor (CTLL^{hIL-4R}, Idzerda, *et al. J. Exp. Med.* 171:861-873 (1990)) were used for competition binding assays. Human IL-13, unlike hIL-4, does not compete for the ¹²⁵I-hIL-4 binding sites on CTLL^{hIL-4R} cells (Figure 8). In similar experiments with the hIL-4R transgenes hIL-13 did not compete for labeled hIL-4 binding sites (e.g. Zurawski *et al. EMBO J.*, 12: 2663-2670 (1993)). On the other hand, hIL-13 is a competitor for ¹²⁵I-hIL-4 crosslinking to the 140 kDa protein (Obiri, *et al., J. Biol. Chem.* 270:8797-8804 (1995); Zurawski, *et al., J. Biol. Chem.* 270:13869-13878 (1995); Vita, *et al., J. Biol. Chem.* 270:3512-3517 (1995)). These results and our results obtained on glioma cells using chimeric toxins indicate that the interaction of hIL-13 with the hIL-4R involves more elements beside the 140 kDa hIL-4R chain.

DISCUSSION

The foregoing experiments show that glioma cells exhibit different responses to hIL-13 and hIL-4-based chimeric proteins containing PE38QQR as well as to the two interleukins themselves when compared to adenocarcinoma cells. All of the studied glioma cell lines are killed potently by hIL-13-PE38QQR and these killing activities are blocked specifically by an excess of hIL-13. On an array of established human glioma cell lines, and represented by the U-273, U-251, DBTRG MG, Hs-683, U-87 MG, SNB-19, and A-172 cell lines, hIL-4 cannot block the action of hIL-13-based chimeric protein. The same phenomenon was observed on primary cultured human glioma cells. Thus, the data indicate that there exists a form of internalized receptor for hIL-13 on glioma cells which does not interact with hIL-4. Of interest a, corresponding

to hIL-13-PE-38QQR, hIL-4-based chimeric protein, hIL-4-PE38QQR, is weakly active or not active through specific binding to the hIL-4 binding protein (Table 6). This is seen on the same cell lines which do respond very well to hIL-13-PE38QQR. Thus, the human IL-13 receptor (hIL-13R) in glioma cells is apparently different from the one described previously ("Adenocarcinomas" in Table 1) (Debinski, *et al.*, *J. Biol. Chem.* 270:16775-16780 (1995)). When hIL-4-PE388QQR, or hIL-4-PE4E, exerts cytotoxic activity, this activity can be nevertheless neutralized by an excess of hIL-13, as it was seen on adenocarcinoma cell lines.

Table 6. Cytotoxic activity of hIL-13 and hIL-4 based chimeric toxins and inhibitory potencies of hIL-13 and hIL-4 to block these activities on cancer cells.

	hIL-13-PE38QQR cytotoxicity			hIL-4-PE38QQR cytotoxicity		
	w/o ILs	w hIL-13	w hIL-4	wo ILs	w hIL-13	w hIL-4
Gliomas	++++ ^a	-	++++	++/-	-	-
Adenocar cinomas	+++	-	-	+++	-	-

^a arbitrary estimate of the cytotoxic potency (+ to +++++). cytotoxicity blocked (-)

Studies with a mutated IL-4 first suggested interrelatedness between IL-13 and IL-4 receptors (Zurawski, *et al.*, *EMBO J.* 12: 2663-2670 (1993)). Although the existence of a novel subunit that is shared between the two receptors was postulated, the same group of investigators has recently pointed to an already identified 140 kDa hIL-4R chain as the component of the hIL-13R (Zurawski, *et al.*, *J. Biol. Chem.* 270:13869-13878 (1995)). This support the studies presented herein. The model systems described herein permits the use of wild-type interleukins and facilitates monitoring the effects of hIL-4 or hIL-13 on the hIL-4R-, and hIL-13R-mediated cellular events. In these models the foregoing experiments show reciprocal inhibition of the cytotoxic activities of hIL-4-, and hIL-13-based chimeric toxins by the interleukins alone.

It was previously suggested that, in order to explain this phenomenon, the common form of hIL-13 and hIL-4 receptor on the studied adenocarcinoma cells must be internalized and is composed of a 140 kDa principal subunit of the hIL-4R (Harada, *et*

al., *J. Biol. Chem.* 267:22752-22758 (1992)) and a 70 kDa hIL-13-binding protein (Obiri, *et al.*, *J. Biol. Chem.* 270:8797-8804 (1995)), which is in agreement with emerging consensus.

The data on glioma cells presented herein implicate another, previously undescribed hIL-13R that does not involve the 140 kDa subunit of the hIL-4R. Several observations speak in favor of the existence of such a receptor. First, hIL-4-PE38QQR has a very weak activity on most of the glioma cells tested. This result is surprising, since hIL-4-PE38QQR tended to be, *e.g.*, more active from the corresponding hIL-13-toxin on several adenocarcinoma cell lines. Therefore, glioma cells should express relatively low levels of hIL-4 binding sites (as compared to number of hIL-13 sites) which, in fact, has already been documented (Puri, *et al.*, *Int. J. Cancer* 58:574-581 (1994)). However, even at these levels of hIL-4R expression one would expect better cytotoxic activity of hIL-4-PE38QQR on these cells (Table 1). Second, the data presented herein show the lack of involvement of the 140 kDa chain in a hIL-13-evoked growth-inhibitory effect on human renal cell carcinoma cells. Third, hIL-4 is deprived of any ability to influence the action of hIL-13-PE388QQR on glioma cells, including freshly cultured explant cells, at even 1000-fold molar excess over the chimeric toxin. This finding is supported by the data obtained herein on renal cell carcinoma cells and indicates the presence of cancer-specific receptor for hIL-13.

Binding experiments using ¹²⁵I-hIL-13 also showed the lack of hIL-4 competition for the radiolabeled ligand binding sites. However, the hIL-4R that is present on, *e.g.*, U-251 MG cells interacts with hIL-13, since hIL-13 blocks the cytotoxicity of hIL-4-PE38QQR. hIL-13 appears to be a good competitor for ¹²⁵I-hIL-4 binding sites in a competitive binding assay on glioma cells. On the other hand, hIL-13 does not compete for ¹²⁵I-hIL-4 binding sites on cells transfected with the 140 kDa hIL-4R alone. This suggests that the expression of 140 kDa hIL-4R is necessary but not sufficient for the interaction with hIL-13. The specific molecular forms of this and other hIL-13 receptor forms are currently being revealed. One common feature of all these forms is their ability to undergo internalization readily upon binding a ligand, as evidenced by the high effectiveness of hIL-13-toxin on various cancer cell lines and explant cells.

Established human glioma cells express up to 30,000 binding sites for hIL-13 per cell and the explant cells even 10 times more. These binding sites represent a new attractive target for the treatment of brain cancers. Since human glioma established cell lines and also human glioma explant cells express an IL-4-independent hIL-13R, it is possible to take advantage of this phenomenon pharmacologically.

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference for all purposes.

WHAT IS CLAIMED IS:

1. A method for specifically delivering an effector molecule to a tumor cell bearing an IL-13 receptor, said method comprising the steps of:
providing a chimeric molecule comprising an effector molecule attached
5 to a targeting molecule that specifically binds to an IL-13 receptor; and
contacting said tumor cell with said chimeric molecule in the presence of
a blocker of an interleukin-4 receptor (IL-4R); wherein said blocker is present in a
concentration sufficient to block binding of said targeting molecule to said IL-4 receptor;
and wherein said chimeric molecule specifically binds to said tumor cell.
10
2. The method of claim 1, wherein said blocker is selected from the
group consisting of an interleukin-4, an interleukin-4 antagonist, and an interleukin-4
receptor binding antibody (anti-IL-4R Ab).
- 15 3. The method of claim 1, wherein said blocker specifically binds to the
140 kDa subunit of the IL-4 receptor.
4. The method of claim 2, wherein said blocker is an interleukin
antagonist that is an interleukin-4 having a mutation in α -helix D.
20
5. The method of claim 4, wherein said interleukin-4 antagonist is
[Y124D]hIL4 or [R121D, Y124D]hIL4.
6. The method of claim 2, wherein said blocker is an antibody selected
25 from the group consisting of s103, s456, s6g7, sg24, and o2g6.
7. The method of claim 1, wherein said targeting molecule is IL-13.
8. The method of claim 1, wherein said targeting molecule is an
30 anti-IL-13 receptor antibody.

9. The method of claim 1, wherein said tumor is selected from the group consisting of a renal cell carcinoma, a glioma, a brain tumor, and a Kaposi's sarcoma.

5 10. The method of claim 1, wherein said effector molecule is selected from the group consisting of a cytotoxin, a label, a radionuclide, a drug, a prodrug, a liposome, a ligand, and an antibody.

10 11. The method of claim 10, wherein said effector molecule is a cytotoxin selected from the group consisting of a *Pseudomonas* exotoxin, a Diphtheria toxin, a ricin, and an abrin.

12. The method of claim 11, wherein said effector molecule is a *Pseudomonas* exotoxin.

15 13. The method of claim 12, wherein chimeric molecule is a fusion protein.

20 14. The method of claim 13, wherein said a fusion protein is IL-13-PE38QQR.

15. The method of claim 14, wherein said fusion protein is IL-13-PE38QQR and said blocker is [Y124D]hIL4 or [R121D, Y124D]hIL4.

25 16. The method of claim 13, wherein said a fusion protein is IL-13-PE4E.

17. The method of claim 16, wherein said fusion protein is IL-13-PE4E and said blocker is [Y124D]hIL4 or [R121D, Y124D]hIL4.

30 18. A method for impairing growth of tumor cells bearing an IL-13 receptor, said method comprising the steps of:

contacting said tumor with a chimeric molecule comprising:

a targeting molecule that specifically binds a human IL-13 receptor; and

an effector molecule selected from the group consisting of a

5 cytotoxin, a radionuclide, a ligand, an antibody, and a prodrug;

wherein said contacting is in the presence of a blocker of an interleukin receptor (IL-4R); wherein said blocker is present in a concentration sufficient to block binding of said targeting molecule to an IL-4 receptor; and wherein said chimeric molecule specifically binds to said tumor cell.

10

19. The method of claim 18, wherein said blocker is selected from the group consisting of an interleukin-4, an interleukin-4 antagonist, and an interleukin-4 receptor binding antibody (anti-IL-4R Ab).

15

20. The method of claim 18, wherein said blocker specifically binds to the 140 kDa subunit of the IL-4 receptor.

21. The method of claim 19, wherein said interleukin-4 antagonist is an interleukin-4 having a mutation in α -helix D.

20

22. The method of claim 21, wherein said interleukin-4 antagonist is [Y124D]hIL4 or [R121D, Y124D]hIL4.

25

23. The method of claim 19, wherein said blocker is an antibody selected from the group consisting of s103, s456, s6g7, sg24, and o2g6.

24. The method of claim 18, wherein said targeting molecule is an antibody that specifically binds a human IL-13 receptor.

30

25. The method of claim 18, wherein said targeting molecule is a human IL-13.

26. The method of claim 25, wherein said effector molecule is a cytotoxin.

27. The method of claim 26, wherein said cytotoxin is selected from the group consisting of *Pseudomonas* exotoxin, ricin, abrin and *Diphtheria* toxin.

28. The method of claim 27, wherein chimeric molecule is a single-chain fusion protein.

29. The method of claim 27, wherein said cytotoxin is a *Pseudomonas* exotoxin.

30. The method of claim 29, wherein said *Pseudomonas* exotoxin is PE38QQR.

31. The method of claim 30, wherein said *Pseudomonas* exotoxin is PE38QQR and said blocker is [Y124D]hIL4 or [R121D, Y124D]hIL4.

32. The method of claim 29, wherein said *Pseudomonas* exotoxin is PE4E.

33. The method of claim 32, wherein said *Pseudomonas* exotoxin is PE4E and said blocker is [Y124D]hIL4 or [R121D, Y124D]hIL4.

34. The method of claim 25, wherein said tumor cell growth is tumor cell growth in a human.

35. The method of claim 34, wherein said contacting comprises administering said chimeric molecule to the human intravenously, into a body cavity, or into a lumen or an organ.

36. A method of detecting the presence, absence, size or number of tumor cells, said method comprising the steps of:

contacting said tumor cells with a chimeric molecule comprising:

a targeting molecule that specifically binds a human IL-13 receptor; and

a detectable label; wherein said contacting is in the presence of a blocker of an interleukin receptor (IL-4R); and wherein said blocker is present in a concentration sufficient to block binding of said targeting molecule to an IL-4 receptor; and

detecting the presence, absence, or quantity of said label.

37. The method of claim 36, wherein said blocker is selected from the group consisting of an interleukin-4, an interleukin-4 antagonist, and an interleukin-4 receptor binding antibody (anti-IL-4R Ab).

38. The method of claim 36, wherein said blocker specifically binds to the 140 kDa subunit of the IL-4 receptor.

39. The method of claim 37, wherein said blocker is an interleukin antagonist that is an interleukin-4 having a mutation in α -helix D.

40. The method of claim 39, wherein said interleukin-4 antagonist is [Y124D]hIL4 or [R121D, Y124D]hIL4.

41. The method of claim 36, wherein said blocker is an antibody selected from the group consisting of s103, s456, s6g7, sg24, and o2g6.

42. The method of claim 36, wherein said targeting molecule is IL-13.

43. The method of claim 36, wherein said targeting molecule is an anti-IL-13 receptor antibody.

44. A pharmacological composition comprising:
a pharmaceutically acceptable carrier;
a chimeric molecule comprising an effector molecule attached to a
targeting molecule that specifically binds to an IL-13 receptor; and
a blocker of an interleukin receptor (IL-4R).

45. The composition of claim 44, wherein said blocker is selected from the group consisting of an interleukin-4, an interleukin-4 antagonist, and an interleukin-4 receptor binding antibody (anti-IL-4R Ab).

46. The composition of claim 44, wherein said blocker specifically binds to the 140 kDa subunit of the IL-4 receptor.

47. The composition of claim 46, wherein said blocker is an interleukin antagonist that is an interleukin-4 having a mutation in α -helix D.

48. The composition of claim 47, wherein said interleukin-4 antagonist is [Y124D]hIL4 or [R121D, Y124D]hIL4.

49. The composition of claim 45, wherein said blocker is an antibody selected from the group consisting of s103, s456, s6g7, sg24, and o2g6.

50. The composition of claim 44, wherein said blocker is present in a delayed release formulation.


51. The composition of claim 44, wherein said targeting molecule is selected from the group consisting of IL-13, and an anti-IL-13 receptor antibody.

52. The composition of claim 51, wherein said effector molecule is selected from the group consisting of a cytotoxin, a label, a radionuclide, a drug, a liposome, a ligand, and an antibody.

53. The composition of claim 52, wherein chimeric molecule is a single-chain fusion protein.

54. The composition of claim 53, wherein said *Pseudomonas* exotoxin is
5 PE38QQR or PE4E.

FIG. 1






FIG. 2





FIG. 3






FIG. 5A




FIG. 5B

FIG. 6A





FIG. 6B






FIG. 7A




FIG. 7B




FIG. 8

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/15050

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/134.1, 138.1, 143.1, 178.1, 183.1; 435/7.23, 69.6; 530/387.3, 387.7, 391.3, 391.7

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y -- A	FENG et al. Characterization of interleukin-13 receptor in carcinoma cell lines and human blood cells and comparison with the interleukin-4 receptor. J. Receptor and Signal Transduction Res. 1995, Vol 15, Nos 7 & 8, pages 931-949, see especially Abstract and pages 932 and 947.	1-34 and 36-54 ----- 1-54
Y	DEBINSKI et al. A Novel Chimeric Protein Composed of Interleukin 13 and Pseudomonas Exotoxin is Highly Cytotoxic to Human Carcinoma Cells Expressing Receptors for Interleukin 13 and Interleukin 4. J. Biol. Chem. 14 July 1995, Vol. 270, No. 28, pages 16755-16780, see especially Abstract and pages 16775 and 16779.	1-34 and 36-54

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

16 DECEMBER 1997

Date of mailing of the international search report

26 JAN 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

SUSAN UNGAR

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/15050

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PURI et al. Targeting of Interleukin-13 Receptor on Human Renal Cell Carcinoma Cells by a Recombinant Chimeric Protein Comprised of Interleukin 13 and Pseudomonas Exotoxin. J. Urology. 1996, Vol 155 (Supplement), page 585A, see Abstract 1097, see entire document.	1-34 and 36-54
Y	EP 0 604 693 A1 (SCHERING-PLOUGH) 06 July 1994 (06.07.94), see Abstract.	2, 3, 6, 19, 20, 23, 37, 38, 45, 49
Y -- A	KRUSE et al. Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement. The EMBO Journal. 1992, Vol. 11, No. 9, pages 3237-3244, see especially the Abstract.	4, 5, 15, 17, 21, 22, 31, 33, 39, 40, 47, 48 ----- 1-54
Y -- A	TONY et al. Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency. Eur. J. Biochem. 1994, Vol. 225, No. 2, pages 659-665, see especially the Abstract	4, 5, 15, 17, 21, 22, 31, 33, 39, 40, 47, 48 ----- 1-54
Y	THORPE, P.E. Antibody Carriers of Cytotoxic Agents in Cancer Therapy: A Review. In: Monoclonal Antibodies '84: Biological and Clinical Applications. Edited by PINCHERA et al. 1985. pages 475-506, see especially pages 479-485.	8, 10, 18-34, 36-43, 51, 52
Y	PASTAN et al. Recombinant Toxins for Cancer Treatment. Science. 22 November 1991, Vol. 254, pages 1173-1177, see especially Abstract.	8, 10, 11, 18-34, 36-43, 52
Y	DEBINSKI et al. Human Glioma Cells Overexpress Receptors for Interleukin 13 and are Extremely Sensitive to a Novel Chimeric Protein Composed of Interleukin 13 and Pseudomonas Exotoxin. Clin. Cancer Res. November 1995, Vol 1, pages 1253-1258, see especially Abstract and page 1254, column 2..	9, 10, 11
Y	DEBINSKI et al. Interleukin-4 receptors expressed on tumor cells may serve as a target for anticancer therapy using chimeric Pseudomonas exotoxin. Int. J. Cancer. 1994, Vol. 58, No. 5, pages 744-748, see entire document.	16, 17, 54
Y	DEBINSKI et al. A wide range of human cancers express interleukin 4 (IL-4) receptors that can be targeted with chimeric Toxin composed of IL-4 and Pseudomonas exotoxin. J. Biol. Chem. 05 July 1993, Vol. 268, No. 19, pages 14065-14070 see entire document	18-34

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/15050

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,001,225 A (TAYLOR, D.W.) 19 March 1991, see entire document especially column 6.	36-43

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/15050**Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest



The additional search fees were accompanied by the applicant's protest.



No protest accompanied the payment of additional search fees.

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C12N 15/62, 15/24; A61K 38/20, 47/48, 39/395, 39/04; C07K 16/28, 14/21, 19/00, 14/57; C12N 15/31, 1/21; G01N 33/68;

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/134.1, 138.1, 143.1, 178.1, 183.1; 435/7.23, 69.6; 530/387.3, 387.7, 391.3, 391.7

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, CAPLUS, IFIPAT, ANABSTR, AQUASCI, BIOBUSINESS, BIOSIS, BIOTECHABS, CANCERLIT, DDFU, DGENE, DRUGU, EMBASE, LIFESCI, MEDLINE, SCISEARCH
search terms: IL-13R, IL-4R, antibody, pseudomonas, PE38QQR, PE4E, block, treat, cancer, s103, s456, s6g7, sg24, o2g6

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

Group I, claim(s) 1-17 and 44-53, are drawn to a method for specifically delivering an effector molecule to a tumor bearing an IL-13 receptor and a pharmaceutical composition.

Group II, claim(s) 18-35, are drawn to a method of impairing growth of tumor cells bearing an IL-13 receptor.

Group III, claim(s) 36-43, are drawn to a method of detecting tumor cells.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. The species are as follows:

Group I is further subject to election of a single disclosed species:

Species 1: Claims 1 and 44 are generic to a plurality of distinct species comprising blockers of the IL-4 receptor including (a) IL-4 (claims 2 and 45), (b) an IL-4 antagonist (claims 2 and 45), and (c) an IL-4 receptor antibody (claims 2 and 45). If species (b) is elected then claims 4 and 5 will also be searched. If species (c) is elected then claim 6 will also be searched.

Species 2: Claims 1 and 44 are generic to a plurality of distinct species comprising targeting molecules including (a) IL-13 (claims 7 and 51) and (b) anti-IL-13 receptor antibody (claims 8 and 51)

Species 3: Claim 1 is generic to a plurality of distinct species comprising effector molecules including (a) Pseudomonas exotoxin, (claim 11) (b) diphtheria toxin (claim 11), (c) a ricin (claim 11) and (d) an abrin (claim 11). If species (a) is elected then claims 12-17 will also be searched. However species (a) is subject to election of a single disclosed species, as follows:

Species 4: Claims 1 and 11-13 are generic to a plurality of distinct species comprising fusion proteins including (a) IL-13-PE38QQR (claims 14 and 15) and (b) IL-13-PE4E (claim 16).

Group II is further subject to election of a single disclosed species:

Species 1: Claim 18 is generic to a plurality of distinct species comprising blockers of the IL-4 receptor including (a) IL-4 (claim 19), (b) an IL-4 antagonist (claims 19), and (c) an IL-4 receptor antibody (claims 19). If species (b) is elected then claims 21 and 22 will also be searched. If species (c) is elected then claim 23 will also be searched.

Species 2: Claim 18 is generic to a plurality of distinct species comprising targeting molecules including (a) IL-13 (claim 25) and (b) anti-IL-13 receptor antibody (claim 23 and 24)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/15050

Species 3: Claim 18 is generic to a plurality of distinct species comprising effector molecules including (a) *Pseudomonas* exotoxin (claim 27), (b) diphtheria toxin (claim 27), (c) a ricin (claim 27) and (d) an abrin (claim 27). If species (a) is elected then claims 29-33 will also be searched. However species (a) is subject to election of a single disclosed species, as follows:

Species 4: Claims 18, 27 and 29 are generic to a plurality of distinct species comprising *Pseudomonas* exotoxin including (a) PE38QQR (claims 30-31) and (b) PE4E (claims 32-33).

Group III is further subject to election of a single disclosed species:

Species 1: Claim 36 is generic to a plurality of distinct species comprising blockers of the IL-4 receptor including (a) IL-4 (claim 37), (b) an IL-4 antagonist (claims 37), and (c) an IL-4 receptor antibody (claims 37). If species (b) is elected then claims 39 and 40 will also be searched. If species (c) is elected then claim 41 will also be searched.

Species 2: Claim 36 is generic to a plurality of distinct species comprising targeting molecules including (a) IL-13 (claim 42) and (b) anti-IL-13 receptor antibody (claim 43).

The inventions listed as Groups do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Group I contains the special technical feature of a method of delivering an effector molecule to a tumor bearing an IL-13 receptor that is not found in Groups II and III. Group II contains the special technical feature of a method of impairing growth of tumor cells not found in Groups I and III. Group III contains the special technical feature of a method of detecting tumor cells not found in Groups I and II.

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:

Group I.

Species I: Species (a), (b) and (c) lack the same special technical feature because species (a) is drawn to IL-4, species (b) is drawn to an IL-4 antagonist and (c) is drawn to an anti-IL-4R antibody, all of which have different structures and function by different mechanisms.

Species II: Species (a) and (b) lack the same special technical feature because species (a) is drawn to IL-13 and species (b) is drawn to anti-IL-13 receptor antibody, both of which have different structures and function by different mechanisms.

Species III: Species (a)-(d) lack the same special technical feature because species (a) is drawn to *Pseudomonas* exotoxin, (c) is drawn to diphtheria toxin, (c) is drawn to a ricin and (d) is drawn to an abrin, all of which have different structures and function by different mechanisms.

Species IV: Species (a) and (b) lack the same special technical features because species (a) is drawn to IL-13-PE38QQR and species (c) is drawn to IL-13-PE4E, both of which are fusion proteins which have different structures and function by different mechanisms.

Group II.

Species I: Species (a), (b) and (c) lack the same special technical feature because species (a) is drawn to IL-4, species (b) is drawn to an IL-4 antagonist and (c) is drawn to an anti-IL-4R antibody, all of which have different structures and function by different mechanisms.

Species II: Species (a) and (b) lack the same special technical feature because species (a) is drawn to IL-13 and species (b) is drawn to anti-IL-13 receptor antibody, both of which have different structures and function by different mechanisms.

Species III: Species (a)-(d) lack the same special technical feature because species (a) is drawn to *Pseudomonas* exotoxin, (c) is drawn to diphtheria toxin, (c) is drawn to a ricin and (d) is drawn to an abrin, all of which have different structures and function by different mechanisms.

Species IV: Species (a) and (b) lack the same special technical features because species (a) is drawn to PE38QQR and species (c) is drawn to PE4E, both of which have different structures and function by different mechanisms.

Group III.

Species I: Species (a), (b) and (c) lack the same special technical feature because species (a) is drawn to IL-4, species (b) is drawn to an IL-4 antagonist and (c) is drawn to an anti-IL-4R antibody, all of which have different structures and function by different mechanisms.

Species II: Species (a) and (b) lack the same special technical feature because species (a) is drawn to IL-13 and species (b) is drawn to anti-IL-13 receptor antibody, both of which have different structures and function by different mechanisms.

THIS PAGE BLANK (USPTO)